

RESSALVA

Atendendo solicitação do autor, o texto completo desta dissertação será disponibilizado somente a partir de 27/01/2024.



UNIVERSIDADE ESTADUAL PAULISTA
“JÚLIO DE MESQUITA FILHO”
Câmpus de São José do Rio Preto

Reinaldo dos Santos Theodoro

**Síntese e Avaliação Antibacteriana e Antimicobacteriana de 4-
hidroxiderricina e seus análogos**

São José do Rio Preto
2022

Reinaldo dos Santos Theodoro

**Síntese e Avaliação Antibacteriana e Antimicobacteriana de 4-
hidroxiderricina e seus análogos**

Dissertação apresentada como parte dos requisitos para a obtenção do título de Mestre em Química, junto ao Programa de Pós-Graduação em Química, do Instituto de Biociências, Letras e Ciências Exatas da Universidade Estadual Paulista “Júlio de Mesquita Filho”, Câmpus de São José do Rio Preto.

Financiadora: FAPESP – Proc. 2019/11979-4

Orientador: Prof. Dr. Luis Octávio Regasini

Coorientador: Dr. Miguel Divino da Rocha

São José do Rio Preto
2022

T388s

Theodoro, Reinaldo dos Santos

Síntese e Avaliação Antibacteriana e Antimicobacteriana de
4-hidroxiclorotetraciclina e seus análogos / Reinaldo dos Santos Theodoro. --
São José do Rio Preto, 2024

315 p.: il., tabs., fotos, mapas

Dissertação (mestrado) - Universidade Estadual Paulista (Unesp),
Instituto de Biociências Letras e Ciências Exatas, São José do Rio
Preto

1. Química. 2. Química medicinal. 3. Química orgânica. I. Título.

Sistema de geração automática de fichas catalográficas da Unesp. Biblioteca do Instituto de
Biociências Letras e Ciências Exatas, São José do Rio Preto. Dados fornecidos pelo autor(a).

Essa ficha não pode ser modificada.

Reinaldo dos Santos Theodoro

**Síntese e Avaliação Antibacteriana e Antimicobacteriana de 4-
hidroxiderricina e seus análogos**

Dissertação apresentada como parte dos requisitos para a obtenção do título de Mestre em Química, junto ao Programa de Pós-Graduação em Química, do Instituto de Biociências, Letras e Ciências Exatas da Universidade Estadual Paulista “Júlio de Mesquita Filho”, Câmpus de São José do Rio Preto.

Financiadora: FAPESP: Proc. 2019/11979-4

Comissão Examinadora

Prof. Dr. Luis Octávio Regasini (Orientador)
Universidade Estadual Paulista “Júlio de Mesquita Filho” – UNESP

Prof. Dr. Arthur Eugen Kümmerle
Universidade Federal Rural do Rio Janeiro – UFRRJ

Prof. Dr. João Henrique Ghilardi Lago
Universidade Federal do ABC – UFABC

São José do Rio Preto
27 de janeiro de 2022

“Fazer o teu melhor, na condição que você tem, enquanto você não tem condições melhores, para fazer melhor ainda”

Mário Sérgio Cortella

Dedico este trabalho à minha família, especialmente, aos meus pais, Cídalina Rodrigues dos Santos Theodoro e Antonio Theodoro Filho (in memória), aos meus irmãos e irmãs, especialmente à Ione dos Santos Theodoro de Carvalho (in memória).

AGRADECIMENTOS

À **Deus**, por me guiar durante todos os momentos ao longo dos momentos bons e nas tempestades da vida.

Aos meus pais, **Cidalina Rodrigues dos Santos Theodoro** e **Antonio Theodoro Filho** (*in memoria*), que sempre me apoiaram nas minhas escolhas e lutas. Os senhores sempre foram minha inspiração e meus heróis, principalmente por serem guerreiros e conseguirem cuidar e educar uma família com 7 filhos mais agregados e nunca desistirem. Aos meus irmãos **Ione dos Santos Theodoro de Carvalho** (*in memoria*), **Celso dos Santos Theodoro**, **Marcelo dos Santos Theodoro**, **Cesar dos Santos Theodoro**, **José Antonio dos Santos Theodoro** e **Iara dos Santos Theodoro** e suas famílias que foram mais do que irmãos, foram meus amigos e pilares na minha vida. Agradeço as minhas sobrinhas **Isabela Theodoro** e **Isabele Carvalho** e suas famílias por todo apoio e parceria. Além dos meus pequenos e lindos sobrinhos e sobrinhas **Gustavinho**, **Alice**, **Samuelzinho**, **Laurinha**, **Leticia**, **Leonardo**, **Davi**, **Heitor** e **Valentina** que mantém a minha esperança viva em um futuro melhor. Aos meus cunhados e cunhadas que são como irmãos para mim, principalmente, ao **Cabo PM Celso Luiz de Carvalho** (*in memoria*) pelas resenhas e conversas sobre a vida, que papai do céu o guarde.

Aos meus segundos pais nessa vida, minha madrinha **Vicenta Garcia de Paula** e meu padrinho **Udson Antonio de Paula “Nenza”** (*in memoria*) e sua família, que sempre nos ajudou, principalmente nos momentos mais difíceis quando morávamos em um barraquinho de pau e lona de plástico e nos ajudou a construir a nossa primeira casinha na Vila Baumam em Novo Horizonte, SP. A minha gratidão e da minha família pelo o que vocês fizeram por nós será eterna e levarei até nos meus últimos dias de vida.

À minha namorada **Leticia Ribeiro de Assis** por ser minha parceira de vida, pelo seu amor e carinho por mim e minha família, além de me apoiar em todas as minhas decisões, principalmente nas minhas estratégias sintéticas. Sou grato também pela sua família, a dona **Ivonete** e seu **Samuel** que sempre foram muito receptivos comigo e me trataram como um filho. Obrigado por tudo, principalmente pelas diversões e os churrascos.

A Me. **Julyanna Andrade** e **André Nascentes** pela a amizade e os momentos de confraternização que dividimos juntos. Vocês são incríveis e seres de luz nesse mundo tão cruel e massacrante. Gratidão eterna.

Aos meus brotheres de outras mães, **Nilson Lima, Guilherme Queiroz, Gustavo Queiroz, Otávio Queiroz, Jean Clanse e Fernando Silva** que sempre me apoiaram e foram a minha válvula de escape durante toda a minha vida. Agradeço aos meus amigos **Felipe Mazatti, Josué Alexsander, Victor Augusto, Ivan, RH** que foram meus parças de graduação e que me ajudaram nessa jornada da minha vida.

Ao meu orientador, Prof. Dr. **Luis Regasini**, por todos os ensinamentos. Todas as experiências vividas no decorrer desses 4 anos ficaram como aprendizado. Pela sua história de vida e por tudo o que você conquistou, saiba que eu te admiro.

Ao meu Coorientador Dr. **Miguel D. da Rocha** por toda a paciência e ensinamentos. Aprendi muito com o tempo compartilhado contigo, principalmente sobre a importância de ser criterioso e analista. Admiro sua história de vida e sua luta. Você é um exemplo.

Às agências de fomento, **CAPES, CNPq e FAPESP (2019/11979-4)** pela bolsa de mestrado e auxílio financeiro que foi o salário mais alto que consegui em todos os trabalhos que fiz em minha vida, e sem os quais a realização desse trabalho seria impossível para o filho de um cortado de cana e empregada doméstica que sempre lutaram por mim e pelos meus irmãos.

Aos amigos que passaram pelo Laboratório de Antibióticos e Quimioterápicos – LAQ. Agradeço, em especial, à Me. **Leticia Ribeiro**, Dr. **Miguel D. da Rocha**, Me. **Julyanna Andrade**, Me. **Veridianna Pattini**, Me. **Julio Sanches**, Me. **Dinis Caina**, Me. **Maria Beatriz**, Me. **Rodrigo Lemos** pela amizade, apoio emocional, discussões científicas, auxílio na execução dos experimentos e, principalmente, por tornarem esses 4 anos (desde IC) tão especiais. Vocês são amigos que levarei para sempre

Aos alunos que tive o prazer de coorientar em seus trabalhos de Iniciação Científica durante meu mestrado, **Ana Luiza, Amabila Luiza e Ruan Felipe**. Acreditem, quem mais aprendeu nessa caminhada fui eu porque pude dividir meu conhecimento com vocês. Foi uma troca mútua. Obrigado por tudo.

Ao Prof. Dr. **Carlos Henrique Gomes Martins** e as suas alunas **Meliza Arantes de Souza Bessa e Ralciane de Paula Menezes**, Universidade Federal de Uberlândia, Laboratório de Ensaios Antimicrobianos – LEA, pelos ensaios antimicrobianos contra as bactérias Gram-positivas e Gram-negativas e Micobactérias.

Ao Prof. Dr. **André Tempone** e seus alunos, Centro de Parasitologia e Micologia, Instituto Adolfo Lutz, pelos ensaios antibacterianos contra os isolados clínicos resistentes aos fármacos.

À Me. **Veridinna Pattini**, Me. **Julyanna Andrade**, Me. **Thiago Lemes** e a Profa. Dra. **Margarete Almeida**, Faculdade de Medicina de São José do Rio Preto, FAMERP/São José do Rio Preto, pelo auxílio nos estudos contra isolados clínicos de *Tricophyton* e *Candida*.

Ao Me. **Guilherme Dilarri** e Prof. Dr. **Henrique Ferreira**, membros do Laboratório de Genética de Bactérias, Instituto de Biociências, UNESP/Rio Claro, pelo auxílio nos experimentos de ensaio em Membrana de *B. subtilis*.

Ao Centro Multiusuário de Inovação Biomolecular, Instituto de Biociências, Letras e Ciências Exatas, UNESP/São José do Rio Preto (FAPESP – Processo nº 2009/53989-4), especialmente, ao Dr. **Fábio Moraes**, pela realização dos experimentos de Ressonância Magnética Nuclear. À Me. **Dani C Oliveira Lisboa**, Laboratório de Bioenergia (UNESP), pelas análises de HPLC. Aos pesquisadores **Lucas Monteiro Santa Cruz** e **Alan Roberto Costa**, Centro de Contaminantes Orgânicos, Instituto Adolfo Lutz, pelos experimentos de Massas dos compostos.

*“Naquela mesa ele sentava sempre
E me dizia sempre o que é viver melhor
Naquela mesa ele contava histórias
Que hoje na memória eu guardo e sei de cor
Naquela mesa ele juntava gente
E contava contente o que fez de manhã
E nos seus olhos era tanto brilho
Que mais que seu filho
Eu fiquei seu fã...”*

Naquela mesa - Nelson Gonçalves

*“Look, if you had one shot
Or one opportunity
To seize everything you ever wanted
One moment
Would you capture it, or just let it slip? Yo...*

*...You better lose yourself in the music
The moment that you own it
you better never let it go
You only get one shot
Do not miss your chance to blow
Cause opportunity comes once in a lifetime go”*

Lose Yourself - Eminem

RESUMO

As infecções microbianas e a resistência aos antibióticos têm sido os desafios mais significativos que ameaçam a saúde pública atualmente. A 4-hidroxierricina (4HD) é uma chalcona prenilada de ocorrência natural que foi isolada da *Angelica keiskei* (Ashitaba) e demonstra múltiplas atividades farmacológicas, principalmente antibacteriana. Neste contexto, 4HD e três séries de análogos foram planejados, sintetizados e investigados contra bactérias, micobactérias e fungos clinicamente importantes. Este trabalho utilizou a 4-hidroxierricina como protótipo para o planejamento de análogos, os quais foram concebidos pela permutação da subunidade *p*-hidroxila por grupos eletrodoadores e eletro-atratores (Série I), além das modificações nas subunidades 2'-hidroxila, 3'-prenila e 4'-metoxila (Série II) e reduções da cetona α,β -insaturadas (Série III). Foram descritas a síntese de 111 substâncias, incluindo intermediários (68) e substâncias-alvo (45), sendo 26 novas e 8 produtos naturais. As substâncias-alvo (1 - 45) foram preparadas através de reações de Iodações Regiosseletivas, O-Metilações, Proteções, Condensações Aldólicas entre aldeídos e cetonas via catálise básica, Acoplamentos de Suzuki, Rearranjos [1,3]-Sigmatrópicos, Desproteções e reações de Redução. Primeiramente, 4HD se mostrou fortemente ativo contra bactérias e micobactérias com valores de CIM de 1,56 - 400 $\mu\text{g.mL}^{-1}$, principalmente contra bactérias gram-positivas. 4HD apresentou potente atividade inibitória contra biofilme de MSSA e MRSA com valores de CIMB₅₀ de 1,56 e 0,78 $\mu\text{g.mL}^{-1}$, respectivamente. Verificamos também que 4HD tem ação bactericida, por lesar a membrana citoplasmática de *B. subtilis*, com baixa citotoxicidade contra as células HaCaT. 4HD mostrou ser um potente agente antifúngico contra cepas de *T. rubrum* e *T. mentagrophytes* com valores de CIM de 0,9 - 31,2 $\mu\text{g.mL}^{-1}$, e atividade moderada contra *C. auris* com valores de CIM de 31,2 $\mu\text{g.mL}^{-1}$. 4HD agiu sinergicamente e potencializou a atividade da terbinafina em 5 a 10 vezes e do itraconazol em 2 a 4 vezes. Além disso, a membrana celular dos fungos dermatófitos foi o alvo do 4HD, pois o ergosterol exógeno diminuiu consideravelmente sua atividade antifúngica (CIM > 31,2 $\mu\text{g.mL}^{-1}$). As atividades antibacterianas e antimicobacterianas dos derivados chalcônicos **2** - **38** foram de 1,56 a 400 $\mu\text{g.mL}^{-1}$. Estudos de REA sugeriram que 3'-prenila, 2'-hidroxila e 4'-hidroxila são pontos farmacofóricos fundamentais de 4HD para a atividade antibacteriana e antimicobacteriana. Além disso, a troca do grupo prenila em 4HD por um grupo benzila não alterou significativamente a atividade antibacteriana, proporcionando uma relação bioisostérica não-clássica entre essas duas subunidades. Derivados de chalconas reduzidas foram as classes de compostos mais ativos neste trabalho. A estratégia de redução da cetona α, β -insaturada causou aumento na atividade antibacteriana de algumas chalconas inicialmente inativas, como a 4'-O-metilbavachalcona (**16**). Além disso, a redução de 4HD formou as dihidrochalconas **29** e **30** e o 1,3-diarilpropano **35**, que foram mais promissores que seu substrato, principalmente contra MSSA e MRSA. Portanto, a redução da cetona α, β -insaturada de 4HD não levou à perda da atividade antibacteriana. Os compostos **13**, **29**, **30** e **37** mostraram potente atividade na inibição do biofilme de MSSA e MRSA. O composto **29** (4-hidroxi-dihidroxierricina) mostrou baixa citotoxicidade contra células HaCaT. Portanto, a 4-hidroxierricina e seus análogos são promissores agentes antibacterianos e antifúngicos, podendo ser uma alternativa no tratamento e combate às diversas infecções causadas por essas bactérias, micobactérias e fungos. Assim, **4HD** e **29** podem ser considerados compostos líderes promissores para a descoberta de novos fármacos.

Palavras-chave: 4-hidroxierricina, chalconas preniladas, acoplamento de Suzuki, rearranjo sigmatrópico, redução, bactérias, micobactérias, fungos, bioisosterismo, biofilme.

ABSTRACT

Microbial infections and antibiotic resistance have been the most significant challenges threatening the health of society today. 4-hydroxyderricin (4HD) is a naturally occurring prenylated chalcone that has been isolated from *Angelica keiskei* (Ashitaba) and demonstrates multiple pharmacological activities, mainly antibacterial. In this context, 4HD and three series of analogs were designed, synthesized, and investigated against clinically important bacteria, mycobacteria, and fungi. This work used 4-hydroxyderricin as a prototype for the planning of analogs, which were designed by the permutation of the *p*-hydroxyl subunit by electron donor and electro-attracting groups (Series I), changing the 2'-hydroxyl, 3'-prenyl and 4'-methoxyl subunits (Series II) and α,β -unsaturated ketone reductions (Series III). The synthesized 111 substances were described, including intermediates (68) and target substances (45), 26 of which were new and 8 were natural products. The target substances (**1** – **45**) were prepared through Regioselective Iodations, O-Methylations, Protections, Aldol Condensations between aldehydes and ketones on basic catalysis, Suzuki couplings, [1,3]-Sigmatropic Rearrangements, Deprotections, and reactions of Reduction. First, 4HD showed to be strongly active against bacteria and mycobacteria with MIC values of 1.56 – 400 $\mu\text{g.mL}^{-1}$, mainly against gram-positive bacteria. 4HD showed potent inhibitory activity against *S. aureus* MSSA and MRSA biofilm with MIC₅₀ values of 1.56 and 0.78 $\mu\text{g.mL}^{-1}$, respectively. We also found that 4HD has a bactericidal action by damaging the cytoplasmatic membrane of *B. subtilis*, with low cytotoxicity against HaCaT cells. 4HD was shown to be a potent antifungal agent against *T. rubrum*, and *T. mentagrophytes* strains with MIC values of 0.9 – 31.2 $\mu\text{g.mL}^{-1}$ and moderate activity against *C. auris* with MIC values of 31.2 $\mu\text{g.mL}^{-1}$. 4HD acted synergistically and potentiated the activity of terbinafine 5- to 10-fold and itraconazole 2- to 4-fold. The cell membrane of dermatophyte fungi was the target of 4HD since exogenous ergosterol considerably decreased the antifungal activity (MIC > 31.2 $\mu\text{g.mL}^{-1}$). The antibacterial and antimycobacterial activities of the chalcones derivatives **2** – **38** ranged from 1.56 to 400 $\mu\text{g.mL}^{-1}$. SAR studies have suggested that 3'-prenyl, 2'-hydroxyl, and 4'-hydroxyl are fundamental pharmacophoric points of 4HD for antibacterial and antimycobacterial activity. Furthermore, exchanging the prenyl group in 4HD for a benzyl group did not significantly alter the antibacterial activity, providing a non-classical bioisosteric relationship between these two subunits. Reduced chalcones derivatives were the most active compounds classes in this work. The α,β -unsaturated ketone reduction strategy caused an increase in the antibacterial activity of some chalcones that were initially not active, such as 4'-O-methylbavachalcone (**16**). Furthermore, 4HD reduction formed dihydrochalcones **29** and **30** and 1,3-diarylpropane **35**, which were more promising than their substrate, mainly against MSSA and MRSA. Therefore, reduction of α,β -unsaturated ketone from 4HD did not lead to loss of antibacterial activity. Compounds **13**, **29**, **30**, and **37** showed potent activity in inhibiting the biofilm of MSSA and MRSA. Compound **29** (4-hydroxydihydroderricin) showed low cytotoxicity against HaCaT cells. Therefore, 4-hydroxyderricin and its analogs are promising antibacterial and antifungal agents and may be an alternative in treating and combating various infections caused by these bacteria, mycobacteria, and fungi. Thus, 4HD and **29** can be considered promising lead compounds to discover new drugs.

Keywords: 4-hydroxyderricin, Prenylated chalcones, Suzuki coupling, Sigmatropic rearrangement, Reduction, Bacteria, Mycobacteria, Fungi, Bioisosterism, Biofilm.

LIST OF FIGURES

CHAPTER II

Figure 1. The chemical structure of 4HD, a natural compound.....	36
Figure 2. Mechanism of action of 4HD – Enzyme Inhibition of <i>S. aureus</i>	38
Figure 3. The pharmacological activities and some underlying mechanisms of 4-hydroxyderricin (4HD). 4HD is a natural compound with various pharmacological effects such as anti-microbial, anti-cancer, anti-oxidant, anti-inflammatory, and others.....	50

CHAPTER III

Figure 1. 4-hydroxyderricin (4HD).....	57
Figure 2. Biofilm inhibition graph of <i>S. aureus</i> 6538 (MSSA). Graph 1.A) Inhibition biofilm in MSSA by 4HD (0.195 to 400 µg/mL). Graph 1.B) Inhibition biofilm in MSSA by vancomycin (0.0115 to 5.9 µg/mL). The MIC _{B50} values are the values represented by the hatched columns.....	63
Figure 3. Biofilm inhibition graph of <i>S. aureus</i> BAA44 (MRSA). Graph 2.A) Inhibition biofilm in MRSA by 4HD (0.195 to 400 µg/mL). Graph 2.B) Inhibition of biofilm in MRSA by vancomycin (0.0115 to 5.9 µg/mL). The BMIC ₅₀ values are the values represented by the hatched columns.....	64
Figure 4. Graph REMA. Percentage of <i>B. subtilis</i> cells inhibited by the 4HD	64
Figure 5. Graph Cells permeabilized. Percentage of <i>B. subtilis</i> cells with permeabilized membrane after exposure to the 4HD . C, cells treated with 4HD at the bactericidal concentration for 15 min.; PC, positive control for permeability (Nisin); NC, negative control.....	65
Figure 6. Fluorescence Microscopy. The cytoplasmic membrane is the primary target of the 4HD . Cells of <i>B. subtilis</i> were stained with the Live/Dead BacLight kit after 15 minutes of contact with the 4HD . Cells with intact membranes are represented in blue, while the cells with damaged membranes are shown in red. A) negative control, untreated <i>B. subtilis</i> ; B) positive control, cells treated with Nisin; C) 4HD at its bactericidal concentration after 15 minutes of contact. Scale bar 5 µm; magnification of 100×.....	66

Figure 7. Effect of different concentrations of 4-hydroxyderricin (4HD) and a chlorhexidine (CHX) on the viability of human keratinocytes cells (HaCat). The results are expressed as means $\pm$ SDs. ^a Different lowercase letters show statistical difference between groups, considering each concentration separately, according to ANOVA and Tukey's test ($p < 0.05$).....67

CHAPTER IV

Figure 1. Natural product 4-hydroxyderricin (4HD).....81

CHAPTER V

Figure 1. Molecular design of Novel Diarylpronane (**4HD-diaryl**) from 4-hydroxyderricin (**4HD**).....94

Figure 2. Graph REMA. Percentage of *B. subtilis* cells inhibited by the **4HD-diaryl** at different concentrations.....99

Figure 3. Antibacterial activity of Chalcone (**DH-X**) and dihydrochalcone (**DHX-H**) bacteria by Sugamoto et al. compared to 4HD-diaryl.....100

Figure 4. Graph microscopy. Percentage of *B. subtilis* cells with permeabilized membrane after exposure to the compound. PC, cells treated with Nisin (positive control for permeability); C, cells treated with 4HD-diaryl at the bactericidal concentration for 15 minutes; NC, negative control.....101

Figure 5. Fluorescence Microscopy. The cytoplasmic membrane is the primary target of the compound. Cells of *B. subtilis* were stained with the Live/Dead BacLight kit after 15 minutes of contact with the compound. Cells with intact membranes are represented in blue, while the cells with damaged membranes are shown in red. **A)** negative control, untreated *B. subtilis*; **B)** positive control, cells treated with Nisin; **C)** compound at its bactericidal concentration after 15 minutes of contact. Scale bar 5 μ m; magnification of 100 $\times$101

Figure 6. Biofilm Inhibition Graph. Biofilm inhibition activity graph against *S. aureus* BAA44 (MRSA) and *S. aureus* 6538 (MSSA) of 4HD-diaryl and positive control (vancomycin). The MICB₅₀ values are the values represented by the hatched columns. **A)** Inhibition of biofilm in MRSA by 4HD-diaryl (0.195 to 400 μ g/mL). **B)** Inhibition of biofilm in MRSA by vancomycin (0.0115 to 5.9 μ g/mL). **C)** Inhibition of biofilm in MSSA by 4HD-

diaryl (0.195 to 400 µg/mL). **D)** Inhibition of biofilm in MSSA by vancomycin (0.0115 to 5.9 µg/mL).....104

Figure 7. Hemolytic activity of 4HD-diaryl in BALB/c mice erythrocytes. The hemolysis was determined colorimetrically at 570 nm in a plate reader. Ultrapure water (MilliQ) was used as a positive control (100% hemolysis) and PBS as a negative control (0%).....105

CHAPTER VI

Figure 1. Biofilm inhibition graph of *S. aureus* 6538 (MSSA). **Graph 1.A, 1.B, 1.C and 1.D)** Inhibitions of biofilm in MSSA by **13, 29, 30 and 37** (0.195 to 400 µg/mL). **Graph 1.E)** Inhibition biofilm in MSSA by vancomycin (0.0115 to 5.9 µg/mL). The MIC_{B50} values are the values represented by the hatched columns.....155

Figure 2. Biofilm inhibition graph of *S. aureus* BAA44 (MRSA). **Graph 2.A, 2.B, 2.C and 2.D)** Inhibitions of biofilm in MSSA by **13, 29, 30 and 37** (0.195 to 400 µg/mL). **Graph 2.E)** Inhibition biofilm in MSSA by vancomycin (0.0115 to 5.9 µg/mL). The MIC_{B50} values are the values represented by the hatched columns.....157

Figure 3. Effect of different concentrations of 4-hydroxydihydroderricin (**29**) and a chlorhexidine (CHX) on the viability of human keratinocytes cells (HaCat). The results are expressed as means ± SDs. ^{a,b} Different lowercase letters show statistical difference between groups, considering each concentration separately, according to ANOVA and Tukey's test (p <0.05).....158

CHAPTER VII

APPENDIX A.

Figure A.1. I) ¹H NMR spectrum of compound **3** (600 MHz – CDCl₃).....224

Figure A.2. I) ¹H NMR spectrum of compound **4** (600 MHz – acetone-*d*₆).....224

Figure A.3. I) ¹H NMR spectrum of compound **6** (600 MHz – CDCl₃).....225

Figure A.4. I) ¹H NMR spectrum of compound **7** (600 MHz – CDCl₃).....225

Figure A.5. I) ¹H NMR spectrum of 4-hydroxyderricin (**1**) (600 MHz – acetone-*d*₆).....225

Figure A.5. II) ¹³C NMR spectrum of 4-hydroxyderricin (**1**) (150 MHz – Acetone-*d*₆).....226

Figure A.5. III) HPLC chromatogram of 4-hydroxyderricin (**1**). Methanol:Water (3:1), 254 nm.....226

Figure A.6. IV) Experimental Mass Spectra (MS) of 4-hydroxyderricin (**1**).....227

APPENDIX B.

Figure B.1. I) ^1H NMR spectrum of compound 4HD-diaryl (600 MHz – acetone- d_6).....	229
Figure B.1. II) ^{13}C NMR spectrum of compound 4HD-diaryl (150 MHz – Acetone- d_6).....	239
Figure B.1. III) HPLC chromatogram of compound 4HD-diaryl . Methanol:Water (3:1), 254 nm.....	230
Figure B.1. IV) Theoretical and Experimental Mass Spectra (MS) of compound 4HD-diaryl	230
Figure B.1. V) Mass spectra (MS/MS), precursor ion m/z 327.1964 [$\text{M} + \text{H}^+$] (Experimental and Theoretical).....	230

APPENDIX C.

Figure C1. I) ^1H NMR spectrum of compound 40 (600 MHz – CDCl_3).....	231
Figure C1. II) ^{13}C NMR spectrum of compound 40 (150 MHz – CDCl_3).....	231
Figure C2. I) ^1H NMR spectrum of compound 41 (600 MHz – CDCl_3).....	232
Figure C2. II) ^{13}C NMR spectrum of compound 41 (150 MHz – CDCl_3).....	232
Figure C3. I) ^1H NMR spectrum of compound 42 (600 MHz – CDCl_3).....	232
Figure C4. I) ^1H NMR spectrum of compound 1a (600 MHz – CDCl_3).....	233
Figure C4. II) ^{13}C NMR spectrum of compound 1a (150 MHz – CDCl_3).....	233
Figure C5. I) ^1H NMR spectrum of compound 1b (600 MHz – CDCl_3).....	234
Figure C5. II) ^{13}C NMR spectrum of compound 1b (150 MHz – CDCl_3).....	234
Figure C6. I) ^1H NMR spectrum of compound 1 (600 MHz – Acetone- d_6).....	235
Figure C6. II) ^{13}C NMR spectrum of compound 1 (150 MHz – Acetone- d_6).....	235
Figure C6. III) HPLC chromatogram of compound 1 . Methanol:Water (3:1), 254 nm.....	236
Figure C7. I) ^1H NMR spectrum of compound 2 (600 MHz – Acetone- d_6).....	236
Figure C7. II) ^{13}C NMR spectrum of compound 2 (150 MHz – Acetone- d_6).....	237
Figure C7. III) HPLC chromatogram of compound 2 . Methanol:Water (3:1), 254 nm.....	237
Figure C8. I) ^1H NMR spectrum of compound 3 (600 MHz – Acetone- d_6).....	238
Figure C8. II) ^{13}C NMR spectrum of compound 3 (150 MHz – Acetone- d_6).....	238
Figure C8. III) HPLC chromatogram of compound 3 . Methanol:Water (3:1), 254 nm.....	239
Figure C9. I) ^1H NMR spectrum of compound 4 (600 MHz – CDCl_3).....	239
Figure C9. II) ^{13}C NMR spectrum of compound 4 (150 MHz – CDCl_3).....	240
Figure C9. III) HPLC chromatogram of compound 4 . Methanol:Water (4:1), 254 nm.....	240
Figure C10. I) ^1H NMR spectrum of compound 5 (600 MHz – Acetone- d_6).....	241

Figure C10. II) ^{13}C NMR spectrum of compound 5 (150 MHz – Acetone- d_6).....	241
Figure C10. III) HPLC chromatogram of compound 5 . Methanol:Water (4:1), 254 nm.....	242
Figure C11. I) ^1H NMR spectrum of compound 6 (600 MHz – Acetone- d_6).....	242
Figure C11. II) ^{13}C NMR spectrum of compound 6 (150 MHz – Acetone- d_6).....	243
Figure C11. III) HPLC chromatogram of compound 6 . Methanol:Water (4:1), 254 nm.....	243
Figure C12. I) ^1H NMR spectrum of compound 7 (600 MHz – CDCl_3).....	244
Figure C12. II) ^{13}C NMR spectrum of compound 7 (150 MHz – CDCl_3).....	244
Figure C12. III) HPLC chromatogram of compound 7 . Methanol:Water (4:1), 254 nm.....	245
Figure C13. I) ^1H NMR spectrum of compound 8 (600 MHz – Acetone- d_6).....	245
Figure C13. II) ^{13}C NMR spectrum of compound 8 (150 MHz – Acetone- d_6).....	246
Figure C13. III) HPLC chromatogram of compound 8 . Methanol:Water (4:1), 254 nm.....	246
Figure C14. I) ^1H NMR spectrum of compound 9 (600 MHz – CDCl_3).....	247
Figure C14. II) ^{13}C NMR spectrum of compound 9 (150 MHz – CDCl_3).....	247
Figure C14. III) HPLC chromatogram of compound 9 . Methanol:Water (4:1), 254 nm.....	248
Figure C15. I) ^1H NMR spectrum of compound 10 (600 MHz – CDCl_3).....	248
Figure C15. II) ^{13}C NMR spectrum of compound 10 (150 MHz – CDCl_3).....	249
Figure C15. III) HPLC chromatogram of compound 10 . Methanol:Water (4:1), 254 nm.....	249
Figure C16. I) ^1H NMR spectrum of compound 11 (600 MHz – CDCl_3).....	250
Figure C16. II) ^{13}C NMR spectrum of compound 11 (150 MHz – CDCl_3).....	250
Figure C16. III) HPLC chromatogram of compound 11 . Methanol:Water (3:1), 254 nm.....	251
Figure C17. I) ^1H NMR spectrum of compound 12 (600 MHz – Acetone- d_6).....	251
Figure C17. II) ^{13}C NMR spectrum of compound 12 (150 MHz – Acetone- d_6).....	252
Figure C17. III) HPLC chromatogram of compound 12 Methanol:Water (3:1), 254 nm.....	252
Figure C18. I) ^1H NMR spectrum of compound 56 (600 MHz – CDCl_3).....	253
Figure C18. II) ^{13}C NMR spectrum of compound 56 (150 MHz – CDCl_3).....	253
Figure C19. I) ^1H NMR spectrum of compound 59 (600 MHz – CDCl_3).....	253
Figure C20. I) ^1H NMR spectrum of compound 60 (600 MHz – CDCl_3).....	254
Figure C21. I) ^1H NMR spectrum of compound 13a (600 MHz – CDCl_3).....	254
Figure C22. I) ^1H NMR spectrum of compound 14a (600 MHz – CDCl_3).....	255
Figure C23. I) ^1H NMR spectrum of compound 13b (600 MHz – Acetone- d_6).....	255
Figure C23. II) ^{13}C NMR spectrum of compound 13b (150 MHz – Acetone- d_6).....	256
Figure C23. III) HPLC chromatogram of compound 13b . Methanol:Water (3:1), 254 nm...	256
Figure C24. I) ^1H NMR spectrum of compound 14b (600 MHz – Acetone- d_6).....	257
Figure C24. II) ^{13}C NMR spectrum of compound 14b (150 MHz – Acetone- d_6).....	257

Figure C24. III) HPLC chromatogram of compound 14b . Methanol:Water (3:1), 254 nm....	258
Figure C25. I) ^1H NMR spectrum of compound 13 (600 MHz – Acetone- d_6).....	258
Figure C25. II) ^{13}C NMR spectrum of compound 13 (150 MHz – Acetone- d_6).....	259
Figure C25. III) HPLC chromatogram of compound 13 . Methanol:Water (3:1), 254 nm.....	259
Figure C26. I) ^1H NMR spectrum of compound 14 (600 MHz – Acetone- d_6).....	260
Figure C26. II) ^{13}C NMR spectrum of compound 14 (150 MHz – Acetone- d_6).....	260
Figure C26. III) HPLC chromatogram of compound 14 . Methanol:Water (4:1), 254 nm.....	261
Figure C27. I) ^1H NMR spectrum of compound 15a (600 MHz – CDCl_3).....	261
Figure C28. I) ^1H NMR spectrum of compound 15 (600 MHz – Acetone- d_6).....	262
Figure C28. II) ^{13}C NMR spectrum of compound 15 (150 MHz – Acetone- d_6).....	262
Figure C28. III) HPLC chromatogram of compound 15 . Methanol:Water (4:1), 254 nm.....	263
Figure C29. I) ^1H NMR spectrum of compound 63 (600 MHz – acetone- d_6).....	263
Figure C30. I) ^1H NMR spectrum of compound 62 (600 MHz – CDCl_3).....	264
Figure C31. I) ^1H NMR spectrum of compound 65 (600 MHz – CDCl_3).....	264
Figure C32. I) ^1H NMR spectrum of compound 66 (600 MHz – CDCl_3).....	265
Figure C33. I) ^1H NMR spectrum of compound 4HDa (600 MHz – CDCl_3).....	265
Figure C34. I) ^1H NMR spectrum of compound 16a (600 MHz – CDCl_3).....	266
Figure C35. I) ^1H NMR spectrum of compound 17a (600 MHz – CDCl_3).....	266
Figure C36. I) ^1H NMR spectrum of compound 16 (600 MHz – Acetone- d_6).....	267
Figure C36. II) ^{13}C NMR spectrum of compound 16 (150 MHz – Acetone- d_6).....	267
Figure C36. III) HPLC chromatogram of compound 16 . Methanol:Water (3:1), 254 nm.....	268
Figure C37. I) ^1H NMR spectrum of compound 17 (600 MHz – Acetone- d_6).....	268
Figure C37. II) ^{13}C NMR spectrum of compound 17 (150 MHz – Acetone- d_6).....	269
Figure C37. III) HPLC chromatogram of compound 17 . Methanol:Water (7:3), 254 nm.....	269
Figure C38. I) ^1H NMR spectrum of compound 18 (600 MHz – Acetone- d_6).....	270
Figure C38. II) ^{13}C NMR spectrum of compound 18 (150 MHz – Acetone- d_6).....	270
Figure C38. III) HPLC chromatogram of compound 18 . Methanol:Water (4:1), 254 nm.....	271
Figure C39. I) ^1H NMR spectrum of compound 68 (600 MHz – Acetone- d_6).....	271
Figure C40. I) ^1H NMR spectrum of compound 69 (600 MHz – Acetone- d_6).....	272
Figure C41. I) ^1H NMR spectrum of compound 19a (600 MHz – Acetone- d_6).....	273
Figure C42. I) ^1H NMR spectrum of compound 20a (600 MHz – Acetone- d_6).....	273
Figure C43. I) ^1H NMR spectrum of compound 19 (600 MHz – Acetone- d_6).....	274
Figure C43. II) ^{13}C NMR spectrum of compound 19 (150 MHz – Acetone- d_6).....	274
Figure C43. III) HPLC chromatogram of compound 19 . Methanol:Water (4:1), 254 nm.....	274

Figure C44. I) ^1H NMR spectrum of compound 20 (600 MHz – Acetone- d_6).....	275
Figure C44. II) ^{13}C NMR spectrum of compound 20 (150 MHz – Acetone- d_6).....	275
Figure C44. III) HPLC chromatogram of compound 20 . Methanol:Water (4:1), 254 nm.....	276
Figure C45. I) ^1H NMR spectrum of compound 70 (600 MHz – CDCl_3).....	276
Figure C46. I) ^1H NMR spectrum of compound 21a (600 MHz – CDCl_3).....	277
Figure C47. I) ^1H NMR spectrum of compound 21b (600 MHz – CDCl_3).....	277
Figure C48. I) ^1H NMR spectrum of compound 21 (600 MHz – Acetone- d_6).....	278
Figure C48. II) ^{13}C NMR spectrum of compound 21 (150 MHz – Acetone- d_6).....	278
Figure C48. III) HPLC chromatogram of compound 21 . Methanol:Water (3:1), 254 nm.....	279
Figure C49. I) ^1H NMR spectrum of compound 22 (600 MHz – Acetone- d_6).....	279
Figure C49. II) ^{13}C NMR spectrum of compound 22 (150 MHz – Acetone- d_6).....	280
Figure C49. III) HPLC chromatogram of compound 22 . Methanol:Water (4:1), 254 nm.....	280
Figure C50. I) ^1H NMR spectrum of compound 71 (600 MHz – CDCl_3).....	281
Figure C50. II) ^{13}C NMR spectrum of compound 71 (150 MHz – CDCl_3).....	281
Figure C51. I) ^1H NMR spectrum of compound 72 (600 MHz – CDCl_3).....	282
Figure C52. I) ^1H NMR spectrum of compound 23a (600 MHz – CDCl_3).....	282
Figure C53. I) ^1H NMR spectrum of compound 23b (600 MHz – CDCl_3).....	283
Figure C54. I) ^1H NMR spectrum of compound 23 (600 MHz – Acetone- d_6).....	283
Figure C54. II) ^{13}C NMR spectrum of compound 23 (150 MHz – Acetone- d_6).....	284
Figure C54. III) HPLC chromatogram of compound 23 . Methanol:Water (3:1), 254 nm.....	284
Figure C55. I) ^1H NMR spectrum of compound 74 (600 MHz – Acetone- d_6).....	285
Figure C56. I) ^1H NMR spectrum of compound 75 (600 MHz – Acetone- d_6).....	285
Figure C57. I) ^1H NMR spectrum of compound 24a (600 MHz – Acetone- d_6).....	285
Figure C58. I) ^1H NMR spectrum of compound 24b (600 MHz – Acetone- d_6).....	286
Figure C59. I) ^1H NMR spectrum of compound 24 (600 MHz – Acetone- d_6).....	286
Figure C59. II) ^{13}C NMR spectrum of compound 24 (150 MHz – Acetone- d_6).....	286
Figure C59. III) HPLC chromatogram of compound 24 . Methanol:Water (3:1), 254 nm.....	286
Figure C60. I) ^1H NMR spectrum of compound 77 (600 MHz – CDCl_3).....	287
Figure C61. I) ^1H NMR spectrum of compound 25a (600 MHz – CDCl_3).....	287
Figure C62. I) ^1H NMR spectrum of compound 25b (600 MHz – Acetone- d_6).....	287
Figure C63. I) ^1H NMR spectrum of compound 25 (600 MHz – Acetone- d_6).....	288
Figure C63. II) ^{13}C NMR spectrum of compound 25 (150 MHz – Acetone- d_6).....	288
Figure S63. III) HPLC chromatogram of compound 25 . Methanol:Water (3:1), 254 nm.....	289
Figure C64. I) ^1H NMR spectrum of compound 26 (600 MHz – CDCl_3).....	289

Figure C64. II) ^{13}C NMR spectrum of compound 26 (150 MHz – CDCl_3).....	289
Figure C64. III) HPLC chromatogram of compound 26 . Methanol:Water (4:1), 254 nm.....	290
Figure C65. I) ^1H NMR spectrum of compound 27 (600 MHz – CDCl_3).....	290
Figure C65. II) ^1H NMR spectrum of compound 27 (150 MHz – CDCl_3).....	290
Figure C65. III) HPLC chromatogram of compound 27 . Methanol:Water (4:1), 254 nm.....	291
Figure C66. I) ^1H NMR spectrum of compound 28 (600 MHz – CDCl_3).....	291
Figure C66. II) ^1H NMR spectrum of compound 28 (150 MHz – CDCl_3).....	292
Figure C66. III) HPLC chromatogram of compound 28 . Methanol:Water (3:1), 254 nm.....	292
Figure C67. I) ^1H NMR spectrum of compound 29 (600 MHz – Acetone- d_6).....	293
Figure C67. II) ^{13}C NMR spectrum of compound 29 (150 MHz – Acetone- d_6).....	293
Figure C67. III) HPLC chromatogram of compound 29 . Methanol:Water (3:1), 275 nm.....	294
Figure C68. I) ^1H NMR spectrum of compound 30 (600 MHz – Acetone- d_6).....	294
Figure C68. II) ^{13}C NMR spectrum of compound 30 (150 MHz – Acetone- d_6).....	295
Figure C68. III) HPLC chromatogram of compound 30 . Methanol:Water (3:1), 275 nm.....	295
Figure C69. I) ^1H NMR spectrum of compound 31 (600 MHz – Acetone- d_6).....	296
Figure C69. II) ^{13}C NMR spectrum of compound 31 (150 MHz – Acetone- d_6).....	296
Figure C69. III) HPLC chromatogram of compound 31 . Methanol:Water (3:1), 275 nm.....	297
Figure C70. I) ^1H NMR spectrum of compound 32 (600 MHz – Acetone- d_6).....	297
Figure C70. II) ^{13}C NMR spectrum of compound 32 (600 MHz – Acetone- d_6).....	298
Figure C70. III) HPLC chromatogram of compound 32 . Methanol:Water (3:1), 275 nm.....	299
Figure C71. I) ^1H NMR spectrum of compound 33 (600 MHz – Acetone- d_6).....	299
Figure C71. II) ^{13}C NMR spectrum of compound 33 (150 MHz – Acetone- d_6).....	299
Figure C71. III) HPLC chromatogram of compound 33 . Methanol:Water (3:1), 275 nm.....	300
Figure C72. I) ^1H NMR spectrum of compound 34 (600 MHz – Acetone- d_6).....	300
Figure C72. II) ^{13}C NMR spectrum of compound 34 (150 MHz – Acetone- d_6).....	301
Figure C72. III) HPLC chromatogram of compound 34 . Methanol:Water (7:3), 275 nm.....	301
Figure C73. I) ^1H NMR spectrum of compound 35 (600 MHz – Acetone- d_6).....	302
Figure S73. II) ^{13}C NMR spectrum of compound 35 (150 MHz – Acetone- d_6).....	302
Figure C73. III) HPLC chromatogram of compound 35 . Methanol:Water (4:1), 275 nm.....	302
Figure C74. I) ^1H NMR spectrum of compound 36 (600 MHz – Acetone- d_6).....	302
Figure C74. II) ^{13}C NMR spectrum of compound 36 (150 MHz – Acetone- d_6).....	303
Figure C74. III) HPLC chromatogram of compound 36 . Methanol:Water (4:1), 275 nm.....	303
Figure C75. I) ^1H NMR spectrum of compound 37 (600 MHz – Acetone- d_6).....	304
Figure C75. II) ^{13}C NMR spectrum of compound 37 (150 MHz – Acetone- d_6).....	305

Figure C75. III) HPLC chromatogram of compound 37 . Methanol:Water (3:1), 254 nm.....	306
Figure C76. I) ^1H NMR spectrum of compound 38 (600 MHz – Acetone- d_6).....	307
Figure C76. II) ^{13}C NMR spectrum of compound 38 (150 MHz – Acetone- d_6).....	307
Figure C76. III) HPLC chromatogram of compound 38 . Methanol:Water (3:1), 275 nm.....	308

APPENDIX D.

Figure D1. I) ^1H NMR spectrum of compound 82 (600 MHz – Acetone- d_6).....	311
Figure D2. I) ^1H NMR spectrum of compound 83 (600 MHz – Acetone- d_6).....	311
Figure D3. I) ^1H NMR spectrum of compound 84 (600 MHz – Acetone- d_6).	311
Figure D4. I) ^1H NMR spectrum of compound 85 (600 MHz – Acetone- d_6).	311
Figure D4. II) ^{13}C NMR spectrum of compound 85 (150 MHz – DMSO- d_6).	311
Figure D5. I) ^1H NMR spectrum of compound 86 (600 MHz – Acetone- d_6).	311
Figure D5. II) ^{13}C NMR spectrum of compound 86 (150 MHz – Acetone- d_6).....	312
Figure D6. I) ^1H NMR spectrum of compound 87 (600 MHz – Acetone- d_6).	312
Figure D7. I) ^1H NMR spectrum of compound 88 (600 MHz – Acetone- d_6).	312
Figure D8. I) ^1H NMR spectrum of compound 89 (600 MHz – Acetone- d_6).	313
Figure D8. II) ^{13}C NMR spectrum of compound 89 (150 MHz – Acetone- d_6).	313
Figure D9. I) ^1H NMR spectrum of compound 90 (600 MHz – Acetone- d_6).	314
Figure D9. II) ^{13}C NMR spectrum of compound 90 (150 MHz – Acetone- d_6).	314
Figure D10. I) ^1H NMR spectrum of compound 92 (600 MHz – DMSO- d_6).	315
Figure D10. II) ^{13}C NMR spectrum of compound 92 (150 MHz – DMSO- d_6).	315

LIST OF TABLES

CHAPTER II

Table 1. The anti-cancer effects of 4-hydroxyderricin (4-HD).....	40
Table 2. The anti-diabetic and anti-obesity effects of 4-HD.....	43
Table 3. Binding energy (ΔG), docking score, and ADMET data for 4-hydroxyderricin.....	52

CHAPTER III

Table 1. The anti-mycobacterial activity of 4HD	59
Table 2. Antibacterial activity of 4HD	60
Table 3. Synergistic evaluation of 4HD against MSSA and MRSA.....	62

CHAPTER IV

Table 1. Antifungal activity of 4HD	85
Table 2. Synergistic evaluation of 4HD with terbinafine (TERB) and itraconazole (ITRA)...87	
Table 3. The action of 4HD on Cell Wall of <i>Trichophyton Species</i>	88
Table 4. The action of 4HD on the Cell Membrane of <i>Trichophyton Species</i>	88
Table 5. Anti-Candida activity of 4-hydroxyderricin (4HD).....	90

CHAPTER V

Table 1. Antibacterial activity of 4HD-diaryl	96
Table 2. Antibacterial activity in μM of 4HD-diaryl against clinical isolates.....	98
Table 3. Antibacterial effect of combination between 4HD-diaryl and vancomycin against <i>S. aureus</i> strains.....	102

CHAPTER VI

Table 1. Antibacterial activity in MIC ($\mu g.mL^{-1}$) of 4-hydroxyderricin (1) and its analogs 2 – 38	138
Table 2. Anti-mycobacterial activity in MIC of 4-hydroxyderricin (1) and its analogs 2 – 38	143
Table 3. Physicochemical properties of 4HD and analogs 2 – 38	148
Table 4. Synergistic evaluation against MSSA and MRSA.....	150

LISTS OF SCHEMES

CHAPTER III

Scheme 1. Synthetic route for target compound.....	58
---	----

CHAPTER V

Scheme 1. Synthetic route for 4HD-diaryl	95
Scheme 2. Synthesis mechanism for intramolecular cyclization of 4HD-diaryl	95

CHAPTER VI

Scheme 1. Planned analogs from series I and II (2 – 28).....	123
Scheme 2. Planned reduced analogs from series III (29 – 38).....	124
Scheme 3. Regioselective synthesis of 4-hydroxyderricin (4HD, 1).....	125
Scheme 4. Synthesis of the prenylated analogs 2 – 11 by Suzuki coupling.....	126
Scheme 5. Synthesis of analog 12	126
Scheme 6. Synthesis of the benzylated analogs 13 and 14 by [1,3]-sigmatropic rearrangement.....	127
Scheme 7. Synthesis of the benzylated analog 15 by Suzuki coupling.....	127
Scheme 8. Non-regioselective synthesis of 4-hydroxyderricin (4HD) and its analogs 16, 17 , and 18	128
Scheme 9. Synthesis of 19 and 20 by [1,3]-sigmatropic rearrangement.....	129
Scheme 10. Synthesis of 21 by Suzuki coupling.....	129
Scheme 11. Synthesis of 3'-prenylated metochalcone (22).....	130
Scheme 12. Synthesis of 4HD regioisomer (23).....	130
Scheme 13. Synthesis of the simplified 4'-methoxy analog of 4HD (24).....	131
Scheme 14. Synthesis of the simplified 2'-hydroxyl analog of 4HD (25).....	132
Scheme 15. Acetylation of 1, 16 , and 17	132
Scheme 16. Synthesis of dihydrochalcones 29 – 34	133
Scheme 17. Synthesis of 1,3-diarylpropanes analogs 35 – 38	134
Scheme 18. Structure and Activity Relationship (SAR) of 4HD	146

CHAPTER VII

Scheme 1. Synthesis of the diaryl analogs.....	309
Scheme 2. Synthesis of 4-carboxiderricin (92).	315

LIST OF ABBREVIATIONS AND SYMBOLS

δ : chemical shift

4HD: 4-hydroxyderricin

ATCC: American Type Culture Collection

Bs: *Bacillus subtilis*

Ca: *Candida albicans*

Cau: *Candida auris*

CFU: colony-forming unit

CHX: chlorhexidine

d: doublet

dd: double doublet

ddd: double double doublet

dt: double triplet

Ec: *Escherichia coli*

Ef: *Enterococcus faecalis*

FCZ: fluconazole

FDA: Food and Drug Administration

FIC: fractional inhibitory concentration

FICI: fractional inhibitory concentration index

Hp: *Helicobacter pylori*

Hz: Hertz

IC₅₀: concentration required in order to reduce cell viability at 50%

IP: propidium iodide

ITRA: itraconazole

J: coupling constant

Kp: *Klebsiella pneumoniae*

Log *P*: lipophilicity

Log *S*: water solubility

m: multiplet

Ma: *Mycobacterium avium*

MBC: Minimum Bactericidal Concentration

MDR: multidrug resistant

MFC: Minimum Fungicidal Concentration

MIC: Minimum Inhibitory Concentration

MIC_{B50}: Minimum Inhibitory Concentration of Biofilm that inhibited 50% or more

Mk: *Mycobacterium kansasii*

MOM: methoxymethyl protecting group

MRSA: Methicillin-Resistant *Staphylococcus aureus*

MSSA: Methicillin-Sensitive *Staphylococcus aureus*

Mt: *Mycobacterium tuberculosis*

MW: molecular weight

NC: negative control

NMR: Nuclear Magnetic Resonance

NTM: nontuberculous mycobacteria

OP: optical density

Pa: *Pseudomonas aeruginosa*

PC: positive control

ppm: part per million

q: quartet

REMA: resazurin microtiter assay plate

r.t.: room temperature

s: singlet

SAR: structure-activity relationship

Sa: *Staphylococcus aureus*

Se: *Staphylococcus epidermidis*

Sm: *Streptococcus mutans*

Sp: *Streptococcus pneumoniae*

Ss: *Streptococcus sanguinis*

Sso: *Streptococcus sobrinus*

t: triplet

TERB: terbinafine

Tm: *Trichophyton mentagrophytes*

Tr: *Trichophyton rubrum*

VAN: vancomycin

VC: vehicle control

SUMMARY

CHAPTER I: INITIAL CONSIDERATIONS AND OBJECTIVES	30
1. INITIAL CONSIDERATIONS	31
2. OBJECTIVES	32
2.1. General Objectives	32
2.2. Specific Objectives	32

CHAPTER II: Pharmacological activities review of 4-hydroxyderricin, a naturally occurring prenylated chalcone	34
--	----

ABSTRACT	35
1. Introduction	35
2. Pharmacological activities	36
2.1. <i>Anti-microbial effects</i>	36
2.2. <i>Anti-cancer effects</i>	39
2.3. <i>Anti-inflammatory effects</i>	43
2.4. <i>Anti-diabetic and Anti-Obesity effects</i>	43
2.5. <i>Anti-oxidant effects</i>	46
2.6. <i>Anti-thrombotic effects</i>	46
2.7. <i>Anti-depressant effects</i>	47
2.8. <i>Other effects</i>	48
3. Pharmacokinetics, Toxicological, and ADMET Assessment	50
4. Conclusion	52

CHAPTER III: Antibacterial Activity of 4-hydroxyderricin: A Study to Evaluate Anti-Biofilm Activity, Membrane Permeability Effect, Checkerboard, and Cytotoxic Activity	55
--	----

ABSTRACT	56
1. Introduction	56
2. Results and Discussion	57
2.1. <i>Chemistry</i>	58
2.1.1. <i>Synthesis of 4-hydroxyderricin (4HD)</i>	58
2.2. <i>Biological Study</i>	58
2.2.1. <i>Anti-microbial studies</i>	58
• <i>MIC determination against mycobacterial and bacterial species</i>	58

• MIC determination against bacterial species.....	59
2.2.2. Checkerboard Assay.....	61
2.2.3. Biofilm Assay against MSSA and MRSA.....	62
2.2.4. Membrane Permeability Assay with <i>B. subtilis</i>	64
• IC Determination.....	64
• Lived/Dead Assay.....	65
2.2.5. Cytotoxicity test.....	66
3. Conclusion.....	67
4. Experimental.....	68
4.1. Chemistry.....	68
4.1.1. General.....	68
4.1.2. Synthesis of 4-hydroxyderricin (4HD).....	68
4.2. Biological Study.....	71
4.2.1. MIC Determination.....	71
• Bacterial and Mycobacterial Strains.....	71
• Anti-bacterial assay.....	72
• Anti-mycobacterial assay.....	73
• Anti- <i>Helicobacter</i> assay.....	73
4.2.2. Checkboard Assay.....	74
4.2.3. Biofilm assay.....	74
4.2.4. Membrane Permeability Assay with <i>B. subtilis</i>	76
4.2.5. Cytotoxicity assay.....	79
 CHAPTER IV: Antifungal Activity of 4-hydroxyderricin.....	 79
ABSTRACT.....	80
1. Introduction.....	80
2. Results and Discussion.....	81
2.1. Chemistry.....	82
2.1.1. Synthesis of 4-hydroxyderricin (4HD).....	82
2.2. Antifungal Studies.....	82
2.2.1. MIC and MFC determination.....	82
2.2.2. Checkerboard Assay.....	83
2.2.3. The action on Cell Wall – Sorbitol Assay.....	84

2.2.4. <i>The action on the Cell Membrane – Interaction with Ergosterol</i>	85
2.2.5. <i>Cytotoxic Activity</i>	85
2.2.6. <i>Additional anti-Candida assays</i>	86
3. Conclusion	87
4. Experimental	87
4.1. <i>Chemistry</i>	87
4.1.1. <i>Synthesis and Characterization of 4-hydroxyderricin (4HD)</i>	87
4.2. <i>Biological – Antifungal assays</i>	87
4.2.1. <i>MIC and MFC Determination</i>	87
4.2.2. <i>Checkerboard Assay</i>	88
4.2.3. <i>The action of 4-Hydroxyderricin on Cell Wall</i>	89
• <i>Sorbitol Assay</i>	89
4.2.4. <i>The action of 4-hydroxyderricin on the Cell Membrane</i>	89
• <i>Interaction with Ergosterol</i>	89
4.2.5. <i>Cytotoxicity Assay</i>	89

CHAPTER V: Synthesis and Antibacterial Activity of a Novel Diarylpropane from 4-hydroxyderricin: Anti-biofilm, Synergetic Effect, and Membrane Permeability Assay...91

ABSTRACT	92
1. Introduction	92
2. Results and Discussion	94
2.1. <i>Chemistry</i>	94
2.1.1. <i>Synthesis of 4HD-diaryl from 4HD</i>	94
2.2. <i>Biological Study</i>	95
2.2.1. <i>Antibacterial activity - Minimum Inhibitory Concentration (MIC)</i>	95
2.2.2. <i>Membrane Permeability Assay with B. subtilis</i>	99
• <i>Minimal bactericidal concentration (MBC) determination</i>	99
• <i>Lived/Dead Test</i>	100
2.2.3. <i>Checkerboard Assay</i>	101
2.2.4. <i>Minimum Inhibitory Concentration of Biofilm (MICB)</i>	102
2.2.5. <i>Hemolytic Activity</i>	104
3. Conclusion	105
4. Materials and Methods	105

4.1. General.....	105
4.2. Synthesis of 4-hydroxyderricin (4HD) and 4HD-diaryl.....	106
4.3. Biological Study.....	110
4.3.1. Minimum Inhibitory Concentration (MIC) of Isolates Clinical.....	110
4.3.2. Mechanism of action: Membrane Permeability Assay with <i>B. subtilis</i>	110
4.3.3. Checkboard and Biofilm Assay.....	112
• Checkboard Assay	112
• Determination of Biofilm Minimum Inhibitory Concentration (MICB)	113
4.3.4. Hemolytic Assay.....	114

CHAPTER VI: Synthesis and Anti-bacterial activity evaluation of 4-hydroxyderricin and novel prenylated, benzylated and geranylated chalcones and their reduced analogs.....

ABSTRACT	120
1. Introduction	121
2. Results and Discussion	124
2.1. Chemistry.....	124
2.1.1. Regioselective synthesis of 4-hydroxyderricin (1).....	124
2.1.2. Series I.....	125
• Synthesis of analogs 2 – 11	125
• Synthesis of 12	126
2.1.3. Series II.....	126
• Synthesis of 13 and 14	126
• Synthesis of 15	127
• Synthesis of analogs 16 – 18	127
• Synthesis of 19 and 20	128
• Synthesis of 21	129
• Synthesis of 22	129
• Synthesis of 23 – 4HD regioisomer	130
• Synthesis of 24	130
• Synthesis of 25	131
• Synthesis of 26 – 28	132
2.1.4. Series III.....	132
• Synthesis of 29 – 34	132

• Synthesis of 35 – 38	133
2.2. Biological Study.....	134
2.2.1. MIC determination.....	134
• Antibacterial activity.....	134
• Anti-mycobacterial activity.....	140
• Structure and Activity Relationship Study.....	145
2.2.2. Determination of Partition Coefficient (Log P_{O/W}) and Predict Aqueous Solubility (Log S).....	147
2.2.3. Checkerboard Assay.....	149
2.2.4. Biofilm Assay against MSSA and MRSA.....	151
2.2.5. Cytotoxicity test.....	154
3. Conclusion	156
4. Experimental	157
4.1. Chemistry.....	157
4.1.1. General.....	157
4.1.2. Synthesis of 4-hydroxyderricin (1).....	158
4.1.3. Synthesis of 2 – 11	160
4.1.4. Synthesis of 12	167
4.1.5. Synthesis of 13 and 14	167
4.1.6. Synthesis of 15	172
4.1.7. Synthesis of 16, 17, and 18	173
4.1.8. Synthesis of 19 and 20	177
4.1.9. Synthesis of 21	180
4.1.10. Synthesis of 22	182
4.1.11. Synthesis of 23	183
4.1.12. Synthesis of 24	185
4.1.13. Synthesis of 25	187
4.1.14. Synthesis of 26, 27 and 28	189
4.1.15. Synthesis of 29 – 34	191
4.1.16. Synthesis of 35 – 38	195
4.1.17. Partition coefficient (n-octanol/water) measured by HPLC method.....	197
4.1.18. Predict Aqueous Solubility by general solubility equation (GSE)	197
4.2. Biological Study.....	198

4.2.1. MIC Determination.....	198
4.2.2. Checkboard Assay.....	198
4.2.3. Biofilm assay.....	198
4.2.4. Cytotoxicity assay.....	198
 CHAPTER VII: General Conclusions, References, and Appendices.....	200
General Conclusions.....	201
REFERENCES.....	204
APPENDIX A. <i>Supplementary material of chapter III</i>.....	223
APPENDIX B. <i>Supplementary material of chapter V</i>.....	228
APPENDIX C. <i>Supplementary material of chapter VI</i>.....	231
APPENDIX D. <i>Complementary Results</i>.....	308

CHAPTER I

INITIAL CONSIDERATIONS AND OBJECTIVES

CHAPTER I: INITIAL CONSIDERATIONS AND OBJECTIVES.....	30
1. INITIAL CONSIDERATIONS.....	31
2. OBJECTIVES.....	32
2.1. General Objectives.....	32
2.2. Specific Objectives.....	32

1. INITIAL CONSIDERATIONS

Natural products are sources of prototypes for researching and developing new drugs and bioactive substances. In this context, the Laboratório de Antibióticos e Quimioterápicos (LAQ) of the Instituto de Biociências, Letras e Ciências Exatas – UNESP/São José do Rio Preto-SP, uses the structure of natural products derived from plants for the development of new bioactive substances. 4-hydroxyderricin (4HD) is a substance with an α,β -unsaturated ketone, and the isoprenyl, hydroxyl, and methoxyl subunits in its core used in this work as a prototype for planning new antimicrobial agents. It was first isolated from the *Angelica Keiskei* plant, a hardy perennial belonging to Umbelliferae. The herb is called ‘Myeong-II Yeob’ in Korea and ‘Ashitaba’ in Japan, both meaning ‘Tomorrow’s Leaf’ and called by the Korean name “Shinsuncho” meaning “elixir of life”. The first reported 4HD synthesis was by [1,3]-Sigmatropic Rearrangement; however, this methodology was not selective for 4HD synthesis. 4HD has a broad spectrum of biological activities, emphasizing its antibacterial effects. However, 4HD has not been evaluated against resistant multi-drug bacteria such as *M. tuberculosis* and *Staphylococcus*, *Enterococcus*, and *Streptococcus* species. Furthermore, there are no in-depth studies on the pharmacophoric contributions of the 4HD subunits and their primary target on bacteria that demonstrate their antibacterial potential. Moreover, 4HD has not been selectively synthesized in the literature.

In this perspective, 4HD and its analogs were designed, synthesized, and evaluated against bacteria of clinical interest, including *Mycobacterium tuberculosis*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Helicobacter pylori*, *Staphylococcus aureus*, *S. epidermidis*, *Enterococcus faecalis*, *Streptococcus pneumoniae*, *Streptococcus sanguinis*, *Streptococcus sobrinus*, and *Streptococcus mutans*. In addition, 4HD was evaluated against fungi of genus Trichophyton, including the species of *T. rubrum* and *T. mentagrophytes*, and fungi of the genus *Candida*, including the species *C. albicans* and *C. auris*.

The dissertation was organized into seven Chapters (I–VII). In chapter I, the initial considerations of work were presented, and at the end of that chapter, the general objective of the dissertation and the specific objectives of Chapters II–VI. Chapter II contains a literature review article to contextualize the importance of 4-hydroxyderricin, including its broad pharmacological activity spectrum. Chapters III and IV contain the manuscripts obtained from the studies of 4-hydroxyderricin against bacteria and fungi of clinical interest, respectively. While Chapters V and VI cover investigations of synthetic analogs of 4HD against gram-positive and gram-negative bacteria. Chapter V shows the potent activity of a reduced derivative of 4HD against clinical isolates multi-drug resistant. In contrast, Chapter VI shows the selective


synthesis of 4HD and evaluation of the pharmacophoric contributions of 4HD by the antibacterial activity of its analogs against Gram-positive and Gram-negative bacteria. Finally, Chapter VII presents the general conclusions of studies with 4HD and its analogs against bacteria and fungi, in addition to the references and appendices of Chapters III, V, and VI.

General Conclusions

This work used 4-hydroxyderricin as a prototype for the planning of analogs, which were designed by the permutation of the *p*-hydroxyl subunit by electron donor and electro-attracting groups (Series I), changing the 2'-hydroxyl, 3'-prenyl and 4'-methoxyl subunits (Series II) and α,β -unsaturated ketone reductions (Series III). The synthesized 111 substances were described, including intermediates (68) and target substances (45), 26 of which were new and 8 were natural products. The target substances (**1** – **45**) were prepared through Regioselective Iodations, O-Methylations, Protections, Aldol Condensations between aldehydes and ketones on basic catalysis, Suzuki couplings, [1,3]-Sigmatropic Rearrangements, Deprotections, and reactions of Reduction.

4HD demonstrated strongly antibacterial activity against mycobacteria and bacteria species; in addition, it was able to inhibit the MSSA and MRSA biofilm formation at low concentrations. We also found that 4HD has a bactericidal action by damaging the cytoplasmatic membrane of *B. subtilis*. Low cytotoxicity activity was observed for 4HD against HaCat cells. Thus, 4HD is a promising antibacterial compound, which could be an alternative to combat several infections caused by many mycobacteria and bacteria species.

4HD has demonstrated antibacterial activity against gram-positive bacteria, being inactive or weakly active against gram-negative:




- ✓MIC against MSSA and MRSA = 3.12 $\mu\text{g.mL}^{-1}$;
- ✓It showed antibacterial activity against other gram-positive species (*S. epidermidis*, *E. faecalis*, *S. mutans*, *S. sanguinis*, *S. sobrinus*) with a MIC of 1.56 to 12.5 $\mu\text{g.mL}^{-1}$;
- ✓MIC against *M. tuberculosis*, *M. avium*, and *M. kansasii* of 15,56 to 31,25 $\mu\text{g.mL}^{-1}$;
- ✓It inhibited MSSA and MRSA biofilm formation at MIC_{B50} of 1.56 to 0.78 $\mu\text{g.mL}^{-1}$, respectively;
- ✓Caused damage to the plasma membrane of *B. subtilis*;
- ✓It was not against human keratinocytes;

Furthermore, 4HD was a potent antifungal agent against *T. rubrum* and *T. mentagrophytes* strains and moderate activity against *C. auris*. In addition, 4HD acted synergistically and potentiated the activity of the antifungal drugs terbinafine and itraconazole. The cell membrane of

dermatophyte fungi was the main target of 4HD. Thus, our results showed that 4-hydroxyderricin is a promising antifungal agent with low toxicity.


4HD demonstrated antifungal activity against Trichophyton species, being reactive or weakly active against Candida species:



- ✓ MIC against *T. mentagrophytes* = 0,9 – 3,9 $\mu\text{g.mL}^{-1}$;
- ✓ MIC against *T. rubrum* = 0,9 – 31,2 $\mu\text{g/mL}$;
- ✓ 4HD showed synergism when combined with terbinafine and itraconazole against *T. mentagrophytes* and *T. rubrum*;
- ✓ 4HD acts on the cell membrane by inhibiting Ergosterol;

4HD was used as a substrate to obtain a novel diarylpropane (4HD-diaryl, **35**), which demonstrated strongly antibacterial activity against gram-positive bacteria, including ATCC and multidrug-resistant clinical isolates of *Enterococcus*, *Staphylococcus*, and *Bacillus* spp. In addition, 4HD-diaryl was able to inhibit the MSSA and MRSA biofilm formation at low concentrations. We also found that 4HD-diaryl has a bactericidal action by damaging the cytoplasmatic membrane of *B. subtilis*. No cytotoxicity activity was observed for 4HD-diaryl against BALB/c mice erythrocytes. Thus, 4HD-diaryl is a novel promising antibacterial compound, which could be an alternative to combat several infections caused by MDR strains of gram-positive bacteria.


4HD-diaryl has demonstrated antibacterial activity against gram-positive bacteria multi-drug resistant (MDR), being inactive or weakly active against gram-negative:



- ✓ 4HD-diaryl was active against Clinical Isolates of drug-resistant *Enterococcus* and *Staphylococcus* species with MIC of 5 to 20 μM (1.6 to 6.5 $\mu\text{g.mL}^{-1}$);
- ✓ It showed antibacterial activity against other gram-positive species (*S. epidermidis*, *E. faecalis*, *S. mutans*, *S. sanguinis*, *S. sobrinus*) with a MIC of 3.12 to 6.25 $\mu\text{g.mL}^{-1}$;
- ✓ MIC against *M. tuberculosis*, *M. avium*, and *M. kansasii* of 31,25 $\mu\text{g.mL}^{-1}$;
- ✓ It inhibited MSSA and MRSA biofilm formation at MIC₅₀ of 1.56 to 0.78 $\mu\text{g.mL}^{-1}$, respectively;
- ✓ Caused damage to the plasma membrane of *B. subtilis*;
- ✓ It was not toxic against erythrocytes collected from BALB/c mice;

Compounds **13**, **29**, **30**, and **37** showed antibacterial and antimycobacterial activity equal to 4HD. Compound **13** showed that the benzyl subunit has a non-classical bioisosterism with isoprenyl in 4-hydroxyderricin. Compounds **13** and **14** are classic bioisosteres as they both had approximately the same antibacterial potency. Furthermore, analog **29** showed that the α,β -unsaturated ketone in 4HD is not a pharmacophoric group for antibacterial and antimycobacterial activities since the reduced analog **29** was as potent as 4HD. Moreover, compounds **13**, **29**, **30**, and **37** showed potent inhibitory activity against *S. aureus* Biofilms (MSSA and MRSA). Compound **29** was chosen as HIT from the series of compounds evaluated, and its cytotoxic activity was determined against HaCat cells. Low cytotoxicity activity was observed for **29**.

The other analogs also showed antibacterial activity against gram-positive bacteria, being inactive or weakly active against gram-negative bacteria:



- ✓ 14 synthesized substances showed antibacterial activity against gram-positive species (MSSA, MRSA, *S. epidermidis*, *E. faecalis*, *S. mutans*, *S. sanguinis*, *S. sobrinus*) with a MIC of 1.56 to 12.5 $\mu\text{g.mL}^{-1}$;
- ✓ 11 substances showed anti-*H. pylori* activity with MIC from 15.62 to 62.50 $\mu\text{g.mL}^{-1}$;
- ✓ 19 substances showed antimycobacterial activity against *M. tuberculosis*, *M. kansasii* and *M. avium* with a MIC of 15.62 to 62.50 $\mu\text{g.mL}^{-1}$;
- ✓ Compounds **13**, **29**, **30** and **37** inhibited MSSA and MRSA biofilm formation at concentrations from 0.78 to 3.12 $\mu\text{g.mL}^{-1}$;
- ✓ Compound **29** was not toxic against human keratinocytes;

REFERENCES

- AKDAG, A.; WAHAB, A.; BERAN, P.; RULÍŠEK, L.; DRON, P. I.; LUDVÍK, J.; MICHL, J. Covalent Dimers of 1,3-Diphenylisobenzofuran for Singlet Fission: Synthesis and Electrochemistry. **Journal of Organic Chemistry**, vol. 80, no. 1, p. 80–89, 2015. <https://doi.org/10.1021/jo502004r>.
- AKIHISA, T.; KIKUCHI, T.; NAGAI, H.; ISHII, K.; TABATA, K.; SUZUKI, T. 4-Hydroxyderricin from *Angelica keiskei* roots induces caspase-dependent apoptotic cell death in HL60 human leukemia cells. **Journal of Oleo Science**, vol. 60, no. 2, p. 71–77, 2011. <https://doi.org/10.5650/jos.60.71>.
- AKIHISA, T.; MOTOI, T.; SEKI, A.; KIKUCHI, T.; FUKATSU, M.; TOKUDA, H.; SUZUKI, N.; KIMURA, Y. Cytotoxic activities and anti-tumor-promoting effects of microbial transformation products of prenylated chalcones from *Angelica keiskei*. **Chemistry and Biodiversity**, vol. 9, no. 2, p. 318–330, 2012. <https://doi.org/10.1002/cbdv.201100255>.
- AKIHISA, T.; TOKUDA, H.; HASEGAWA, D.; UKIYA, M.; KIMURA, Y.; ENJO, F.; SUZUKI, T.; NISHINO, H. Chalcones and other compounds from the exudates of *Angelica keiskei* and their cancer chemopreventive effects. **Journal of Natural Products**, vol. 69, no. 1, p. 38–42, 2006. <https://doi.org/10.1021/np058080d>.
- AKIHISA, T.; TOKUDA, H.; UKIYA, M.; IIZUKA, M.; SCHNEIDER, S.; OGASAWARA, K.; MUKAINAKA, T.; IWATSUKI, K.; SUZUKI, T.; NISHINO, H. Chalcones, coumarins, and flavanones from the exudate of *Angelica keiskei* and their chemopreventive effects. **Cancer Letters**, vol. 201, no. 2, p. 133–137, 2003. [https://doi.org/10.1016/S0304-3835\(03\)00466-X](https://doi.org/10.1016/S0304-3835(03)00466-X).
- ALVES, J. A.; ABRÃO, F.; SILVA MORAES, T. Da; DAMASCENO, J. L.; DOS SANTOS MORAES, M. F.; SOLA VENEZIANI, R. C.; AMBRÓSIO, S. R.; BASTOS, J. K.; DANTAS MIRANDA, M. L.; GOMES MARTINS, C. H. Investigation of *Copaifera* genus as a new source of antimycobacterial agents. **Future Science OA**, vol. 6, no. 7, 2020. <https://doi.org/10.2144/fsoa-2020-0018>.
- AMARAL, M.; DE SOUSA, F. S.; SILVA, T. A. C.; JUNIOR, A. J. G.; TANIWAKI, N. N.; JOHNS, D. M.; LAGO, J. H. G.; ANDERSON, E. A.; TEMPONE, A. G. A semi-synthetic neolignan derivative from dihydrodieugenol B selectively affects the bioenergetic system of *Leishmania infantum* and inhibits cell division. **Scientific Reports**, vol. 9, no. 1, p. 1–15, 2019. <https://doi.org/10.1038/s41598-019-42273-z>.
- APPENDINO, G.; GIBBONS, S.; GIANA, A.; PAGANI, A.; GRASSI, G.; STAVRI, M.; SMITH, E.; RAHMAN, M. M. Antibacterial cannabinoids from *Cannabis sativa*: A structure-activity study. **Journal of Natural Products**, vol. 71, no. 8, p. 1427–1430, 2008. <https://doi.org/10.1021/np8002673>.
- ARCHER, N. K.; MAZAITIS, M. J.; COSTERTON, J. W.; LEID, J. G.; POWERS, M. E.; SHIRTLIFF, M. E. *Staphylococcus aureus* biofilms Properties, regulation and roles in human disease. **Virulence - Special Focus Review: Biofilms**, vol. 2, no. 5, 2011. .

ARUNG, E. T.; FURUTA, S.; SUGAMOTO, K.; SHIMIZU, K.; ISHIKAWA, H.; MATSUSHITA, Y. I.; KONDO, R. The inhibitory effects of representative chalcones contained in *Angelica keiskei* on melanin biosynthesis in B16 melanoma cells. **Natural Product Communications**, vol. 7, no. 8, p. 1007–1010, 2012. <https://doi.org/10.1177/1934578x1200700812>.

AULIFA, D. L.; ADNYANA, I. K.; LEVITA, J.; SUKRASNO, S. 4-Hydroxyderricin isolated from the sap of *angelica keiskei* koidzumi: Evaluation of its inhibitory activity towards dipeptidyl peptidase-iv. **Scientia Pharmaceutica**, vol. 87, no. 4, p. 3–12, 2019. <https://doi.org/10.3390/scipharm87040030>.

ÁVILA, H. P.; SMÂNIA, E. de F. A.; MONACHE, F. D.; SMÂNIA, A. Structure–activity relationship of antibacterial chalcones. **Bioorganic & Medicinal Chemistry**, vol. 16, no. 22, p. 9790–9794, 2008. DOI 10.1016/j.bmc.2008.09.064. Available at: <http://dx.doi.org/10.1016/j.bmc.2008.09.064>.

AVOGARO, A.; FADINI, G. P. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. **Diabetes Care**, vol. 37, no. 10, p. 2884–2894, 2014. <https://doi.org/10.2337/dc14-0865>.

BABA, K.; NAKATA, K.; TANIGUCHI, M.; KIDO, T.; KOZAWA, M. Chalcones from *Angelica keiskei*. **Phytochemistry**, vol. 29, no. 12, p. 3907–3910, 1990. [https://doi.org/10.1016/0031-9422\(90\)85357-L](https://doi.org/10.1016/0031-9422(90)85357-L).

BAKKE, R.; KOMMEDAL, R.; KALVENES, S. Quantification of biofilm accumulation by an optical approach. **Journal of Microbiological Methods**, vol. 44, no. 1, p. 13–26, 2001. [https://doi.org/10.1016/S0167-7012\(00\)00236-0](https://doi.org/10.1016/S0167-7012(00)00236-0).

BATTENBERG, O. A.; YANG, Y.; VERHELST, S. H. L.; SIEBER, S. A. Target profiling of 4-hydroxyderricin in *S. aureus* reveals seryl-tRNA synthetase binding and inhibition by covalent modification. **Molecular BioSystems**, vol. 9, no. 3, p. 343–351, 2013. <https://doi.org/10.1039/c2mb25446h>.

BERGSTRÖM, M.; SURESH, G.; NAIDU, V. R.; UNELIUS, C. R. N-Iodosuccinimide (NIS) in Direct Aromatic Iodination. **European Journal of Organic Chemistry**, vol. 2017, no. 22, p. 3234–3239, 2017. <https://doi.org/10.1002/ejoc.201700173>.

BESCOS, R.; ASHWORTH, A.; CUTLER, C.; BROOKES, Z. L.; BELFIELD, L.; RODILES, A.; CASAS-AGUSTENCH, P.; FARNHAM, G.; LIDDLE, L.; BURLEIGH, M.; WHITE, D.; EASTON, C.; HICKSON, M. Effects of Chlorhexidine mouthwash on the oral microbiome. **Scientific Reports**, vol. 10, no. 1, p. 1–8, 2020. <https://doi.org/10.1038/s41598-020-61912-4>.

BITENCOURT, T. A.; KOMOTO, T. T.; MASSAROTO, B. G.; MIRANDA, C. E. S.; BELEBONI, R. O.; MARINS, M.; FACHIN, A. L. Trans-chalcone and quercetin down-regulate fatty acid synthase gene expression and reduce ergosterol content in the human pathogenic dermatophyte *Trichophyton rubrum*. **BMC Complementary and Alternative Medicine**, vol. 13,

2013. <https://doi.org/10.1186/1472-6882-13-229>.

BOMBARDELLI, M. E. S. M. F. D. M. United States Patent (19). no. 19, p. 4–7, 1996.

BROOKES, Z. L. S.; BESCOS, R.; BELFIELD, L. A.; ALI, K.; ROBERTS, A. Current uses of chlorhexidine for management of oral disease: a narrative review. **Journal of Dentistry**, vol. 103, no. October, 2020. <https://doi.org/10.1016/j.jdent.2020.103497>.

BROWN, G. D.; DENNING, D. W.; GOW, N. A. R.; LEVITZ, S. M.; NETEA, M. G.; WHITE, T. C. Hidden killers: Human fungal infections. **Science Translational Medicine**, vol. 4, no. 165, p. 1–10, 2012. <https://doi.org/10.1126/scitranslmed.3004404>.

CAESAR, L. K.; KELLOGG, J. J.; KVALHEIM, O. M.; CECH, R. A.; CECH, N. B. Integration of Biochemometrics and Molecular Networking to Identify Antimicrobials in *Angelica keiskei*. **Planta Medica**, vol. 84, no. 9–10, p. 721–728, 2018. <https://doi.org/10.1055/a-0590-5223>.

CAIAFFA, K. S.; MASSUNARI, L.; DANELON, M.; ABUNA, G. F.; BEDRAN, T. B. L.; SANTOS-FILHO, N. A.; SPOLIDORIO, D. M. P.; VIZOTO, N. L.; CILLI, E. M.; DUQUE, C. KR-12-a5 is a non-cytotoxic agent with potent antimicrobial effects against oral pathogens. **Biofouling**, vol. 33, no. 10, p. 807–818, 2017. DOI 10.1080/08927014.2017.1370087. Available at: <http://doi.org/10.1080/08927014.2017.1370087>.

CANTELLI, B. A. M.; BITENCOURT, T. A.; KOMOTO, T. T.; BELEBONI, R. O.; MARINS, M.; FACHIN, A. L. Caffeic acid and licochalcone A interfere with the glyoxylate cycle of *Trichophyton rubrum*. **Biomedicine and Pharmacotherapy**, vol. 96, no. September, p. 1389–1394, 2017. DOI 10.1016/j.biopha.2017.11.051. Available at: <https://doi.org/10.1016/j.biopha.2017.11.051>.

CARVALHO, R. S.; CAROLLO, C. A.; DE MAGALHÃES, J. C.; PALUMBO, J. M. C.; BOARETTO, A. G.; NUNES E SÁ, I. C.; FERRAZ, A. C.; LIMA, W. G.; DE SIQUEIRA, J. M.; FERREIRA, J. M. S. Antibacterial and antifungal activities of phenolic compound-enriched ethyl acetate fraction from *Cochlospermum regium* (mart. Et. Schr.) Pilger roots: Mechanisms of action and synergism with tannin and gallic acid. **South African Journal of Botany**, vol. 114, p. 181–187, 2018. DOI 10.1016/j.sajb.2017.11.010. Available at: <https://doi.org/10.1016/j.sajb.2017.11.010>.

CHANG, H. R.; LEE, H. J.; RYU, J. H. Chalcones from *angelica keiskei* attenuate the inflammatory responses by suppressing nuclear translocation of NF- κ B. **Journal of Medicinal Food**, vol. 17, no. 12, p. 1306–1313, 2014. <https://doi.org/10.1089/jmf.2013.3037>.

CHUNG, M. C.; FERREIRA, E. I. O processo de latencição no planejamento de fármacos. **Química Nova**, vol. 22, no. 1, p. 75–84, 1999. <https://doi.org/10.1590/s0100-40421999000100014>.

CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI). Reference method for broth dilution. **Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3th ed.**, vol. 28, no. 14, p. 0–13, 2008. Available at:

https://clsi.org/media/1461/m27a3_sample.pdf.

CLSI, T. C. and L. S. I. **M07-A10: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically**. [S. l.: s. n.], 2015. Available at: www.clsi.org.

DAINA, A.; MICHIELIN, O.; ZOETE, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. **Scientific Reports**, vol. 7, no. October 2016, p. 1–13, 2017. <https://doi.org/10.1038/srep42717>.

DAN, W.; DAI, J. Recent developments of chalcones as potential antibacterial agents in medicinal chemistry. **European Journal of Medicinal Chemistry**, vol. 187, p. 111980, 2020. DOI 10.1016/j.ejmech.2019.111980. Available at: <https://doi.org/10.1016/j.ejmech.2019.111980>.

DIEGO, A. M. de. Aspectos clínicos, diagnósticos y terapéuticos de las dermatofitosis. **Enfermedades Infecciosas y Microbiología Clínica**, vol. 29, no. SUPPL. 3, p. 33–39, 2011. DOI 10.1016/S0213-005X(11)70025-8. Available at: [http://dx.doi.org/10.1016/S0213-005X\(11\)70025-8](http://dx.doi.org/10.1016/S0213-005X(11)70025-8).

DU, H.; BING, J.; HU, T.; ENNIS, C. L.; NOBILE, C. J.; HUANG, G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. **PLoS Pathogens**, vol. 16, no. 10, p. 1–18, 2020. DOI 10.1371/journal.ppat.1008921. Available at: <http://dx.doi.org/10.1371/journal.ppat.1008921>.

ENOKI, T.; OHNOGI, H.; KOBAYASHI, E.; SAGAWA, H. Anti-diabetic activities of chalcones derived from ashitaba. **Nippon Shokuhin Kagaku Kogaku Kaishi**, vol. 57, no. 11, p. 456–463, 2010. <https://doi.org/10.3136/nshkkk.57.456>.

ENOKI, T.; OHNOGI, H.; NAGAMINE, K.; KUDO, Y.; SUGIYAMA, K.; TANABE, M.; KOBAYASHI, E.; SAGAWA, H.; KATO, I. Antidiabetic activities of chalcones isolated from a Japanese herb, Angelica keiskei. **Journal of Agricultural and Food Chemistry**, vol. 55, no. 15, p. 6013–6017, 2007. <https://doi.org/10.1021/jf070720q>.

ESCALANTE, A.; GATTUSO, M.; PÉREZ, P.; ZACCHINO, S. Evidence for the mechanism of action of the antifungal phytolaccoside B isolated from Phytolacca tetramera Hauman. **Journal of Natural Products**, vol. 71, no. 10, p. 1720–1725, 2008. <https://doi.org/10.1021/np070660i>.

FRÍAS-DE-LEÓN, M. G.; MARTÍNEZ-HERRERA, E.; ATOCHE-DIÉGUEZ, C. E.; GONZÁLEZ-CESPÓN, J. L.; URIBE, B.; ARENAS, R.; RODRÍGUEZ-CERDEIRA, C. Molecular identification of isolates of the trichophyton mentagrophytes complex. **International Journal of Medical Sciences**, vol. 17, no. 1, p. 45–52, 2020. <https://doi.org/10.7150/ijms.35173>.

FROST, D. J.; BRANDT, K. D.; CUGIER, D.; GOLDMAN, R. A whole-Cell Candida albicans Assay for the Detection of Inhibitors towards Fungal Cell Wall Synthesis and Assembly. **The Journal of Antibiotics**, vol. 48 NO. 4, p. 306–310, 1995. .

GARCIA, M. A. R.; THEODORO, R. S.; SARDI, J. C. O.; SANTOS, M. B.; AYUSSO, G. M.; PAVAN, F. R.; COSTA, A. R.; SANTA CRUZ, L. M.; ROSALEN, P. L.; REGASINI, L. O.

Design, synthesis and antibacterial activity of chalcones against MSSA and MRSA planktonic cells and biofilms. **Bioorganic Chemistry**, vol. 116, no. January, p. 105279, 2021. DOI 10.1016/j.bioorg.2021.105279. Available at: <https://doi.org/10.1016/j.bioorg.2021.105279>.

GŁODOWSKA, M.; ŁYSZCZ, M. Cannabis sativa L. and its antimicrobial properties - A review. **Strona**, no. May, p. 77–82, 2016. Available at: https://www.researchgate.net/profile/Martyna_Glodowska/publication/317185536_Cannabis_sativa_L_and_its_antimicrobial_properties_-_A_review/links/592bfd7d458515e3d46eae74/Cannabis-sativa-L-and-its-antimicrobial-properties-A-review.pdf.

GO, M.; WU, X.; LIU, X. Chalcones: An Update on Cytotoxic and Chemoprotective Properties. **Current Medicinal Chemistry**, vol. 12, no. 4, p. 483–499, 2005. <https://doi.org/10.2174/0929867053363153>.

GUPTA, M.; SHARMA, R.; KUMAR, A. Comparative potential of Simvastatin, Rosuvastatin and Fluvastatin against bacterial infection: an in silico and in vitro study. **Oriental Pharmacy and Experimental Medicine**, vol. 19, no. 3, p. 259–275, 2019. DOI 10.1007/s13596-019-00359-z. Available at: <https://doi.org/10.1007/s13596-019-00359-z>.

HAGIWARA, H.; NAKATA, K.; MIYAZAKI, H.; MAEHASHI, S.; KOMIYAMA, Y.; AIDA, R.; YOSHIDA, S.; KOKUBU, D.; HAGIWARA, K.; YOSHIDA, K. 4-Hydroxyderricin inhibits osteoclast formation and accelerates osteoblast differentiation. **Cytotechnology**, vol. 71, no. 1, p. 15–22, 2018. DOI 10.1007/s10616-018-0236-2. Available at: <https://doi.org/10.1007/s10616-018-0236-2>.

HAGIWARA, H.; NAKATA, K.; MIYAZAKI, H.; MAEHASHI, S.; KOMIYAMA, Y.; AIDA, R.; YOSHIDA, S.; KOKUBU, D.; HAGIWARA, K.; YOSHIDA, K. 4-Hydroxyderricin inhibits osteoclast formation and accelerates osteoblast differentiation. **Cytotechnology**, vol. 71, no. 1, p. 15–22, 2019. DOI 10.1007/s10616-018-0236-2. Available at: <https://doi.org/10.1007/s10616-018-0236-2>.

HE, C.; ZHANG, T.; YAMAMOTO, N.; FUKUDA, I.; ASHIDA, H. INHIBITORY EFFECT OF CARDAMONIN ON TRANSFORMATION OF ARYL HYDROCARBON RECEPTOR. **Organohalogen Compounds**, vol. 75, p. 620–624, 2013. .

IBRAHIM, T. S.; ALMALKI, A. J.; MOUSTAFA, A. H.; ALLAM, R. M.; ABUO-RAHMA, G. E. D. A.; EL SUBBAGH, H. I.; MOHAMED, M. F. A. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study. **Bioorganic Chemistry**, vol. 111, no. January, p. 104885, 2021. DOI 10.1016/j.bioorg.2021.104885. Available at: <https://doi.org/10.1016/j.bioorg.2021.104885>.

INAMORI, Y.; BABA, K.; HIROSHI, T.; TANIGUCHI, M.; KOUJI, N.; KOZAWA, M. NII-Electronic Library Service. **Chemical Pharmaceutical Bulletin**, vol. 39, no. 534, p. 364–370, 1991. Available at: <http://www.mendeley.com/research/geology-volcanic-history-eruptive-style-yakedake-volcano-group-central-japan/>.

IZANO, E. A.; AMARANTE, M. A.; KHER, W. B.; KAPLAN, J. B. Differential roles of poly-N-

acetylglucosamine surface polysaccharide and extracellular DNA in *Staphylococcus aureus* and *Staphylococcus epidermidis* biofilms. **Applied and Environmental Microbiology**, vol. 74, no. 2, p. 470–476, 2008. <https://doi.org/10.1128/AEM.02073-07>.

JEFFERY-SMITH, A.; TAORI, S. K.; SCHELENZ, S.; JEFFERY, K.; JOHNSON, E. M.; BORMAN, A.; MANUEL, R.; BROWNA, C. S. *Candida auris*: A review of the literature. **Clinical Microbiology Reviews**, vol. 31, no. 1, 2018. <https://doi.org/10.1128/CMR.00029-17>.

JOHNSON, A. P.; WOODFORD, N. Global spread of antibiotic resistance: The example of New Delhi metallo- β -lactamase (NDM)-mediated carbapenem resistance. **Journal of Medical Microbiology**, vol. 62, no. PART4, p. 499–513, 2013. <https://doi.org/10.1099/jmm.0.052555-0>.

JORGENSEN, W. L.; DUFFY, E. M. Prediction of drug solubility from structure. **Advanced Drug Delivery Reviews**, vol. 54, p. 355–366, 2002. <https://doi.org/10.5414/ALP32453>.

KAMURAI, B.; MOMBESHORA, M.; MUKANGANYAMA, S. Repurposing of Drugs for Antibacterial Activities on Selected ESKAPE Bacteria *Staphylococcus aureus* and *Pseudomonas aeruginosa*. **International Journal of Microbiology**, vol. 2020, 2020. <https://doi.org/10.1155/2020/8885338>.

KAWABATA, K.; KATO, Y.; SAKANO, T.; BABA, N.; HAGIWARA, K.; TAMURA, A.; BABA, S.; NATSUME, M.; OHIGASHI, H. Effects of phytochemicals on in vitro anti-inflammatory activity of *Bifidobacterium adolescentis*. **Bioscience, Biotechnology and Biochemistry**, vol. 79, no. 5, p. 799–807, 2015. DOI 10.1080/09168451.2015.1006566. Available at: <http://dx.doi.org/10.1080/09168451.2015.1006566>.

KAWABATA, K.; SAWADA, K.; IKEDA, K.; FUKUDA, I.; KAWASAKI, K.; YAMAMOTO, N.; ASHIDA, H. Prenylated chalcones 4-hydroxyderricin and xanthoangelol stimulate glucose uptake in skeletal muscle cells by inducing GLUT4 translocation. **Molecular Nutrition and Food Research**, vol. 55, no. 3, p. 467–475, 2011. <https://doi.org/10.1002/mnfr.201000267>.

KHAMENEH, B.; IRANSHAHY, M.; SOHEILI, V.; SEDIGHEH, B.; BAZZAZ, F. Khameneh2019.Pdf. **Antimicrobial Resistance and Infection Control**, vol. 8, p. 1–28, 2019.

KIL, Y. S.; NAM, J. W.; LEE, J.; SEO, E. K. Separation of two major chalcones from *Angelica keiskei* by high-speed counter-current chromatography. **Archives of Pharmacal Research**, vol. 38, no. 8, p. 1506–1511, 2015. DOI 10.1007/s12272-014-0530-2. Available at: <http://dx.doi.org/10.1007/s12272-014-0530-2>.

KIL, Y. S.; PHAM, S. T.; SEO, E. K.; JAFARI, M. *Angelica keiskei*, an emerging medicinal herb with various bioactive constituents and biological activities. **Archives of Pharmacal Research**, vol. 40, no. 6, p. 655–675, 2017. <https://doi.org/10.1007/s12272-017-0892-3>.

KIM, D. W.; CURTIS-LONG, M. J.; YUK, H. J.; WANG, Y.; SONG, Y. H.; JEONG, S. H.; PARK, K. H. Quantitative analysis of phenolic metabolites from different parts of *Angelica keiskei* by HPLC-ESI MS/MS and their xanthine oxidase inhibition. **Food Chemistry**, vol. 153, p. 20–27, 2014a. DOI 10.1016/j.foodchem.2013.12.026. Available at:

<http://dx.doi.org/10.1016/j.foodchem.2013.12.026>.

KIM, D. W.; CURTIS-LONG, M. J.; YUK, H. J.; WANG, Y.; SONG, Y. H.; JEONG, S. H.; PARK, K. H. Quantitative analysis of phenolic metabolites from different parts of *Angelica keiskei* by HPLC-ESI MS/MS and their xanthine oxidase inhibition. **Food Chemistry**, vol. 153, p. 20–27, 2014b. DOI 10.1016/j.foodchem.2013.12.026. Available at: <http://dx.doi.org/10.1016/j.foodchem.2013.12.026>.

KIM, J. H.; SON, Y. K.; KIM, G. H.; HWANG, K. H. Xanthoangelol and 4-hydroxyderricin are the major active principles of the inhibitory activities against monoamine oxidases on *angelica keiskei* K. **Biomolecules and Therapeutics**, vol. 21, no. 3, p. 234–240, 2013. <https://doi.org/10.4062/biomolther.2012.100>.

KIM, S.-J.; LEE, J. J.; YOON, H.-H.; JUN, J.-G. ChemInform Abstract: Synthesis of Biologically Active Natural Component 4-Hydroxyderricin (IIIb) Through Water-Accelerated [3,3]-Sigmatropic Rearrangement [$\rightarrow$ (IIIa)]. **ChemInform**, vol. 45, no. 7, p. no-no, 2014. <https://doi.org/10.1002/chin.201407233>.

KIM, S. J.; LEE, J. J.; YOON, H. H.; JUN, J. G. Synthesis of biologically active natural component 4-hydroxyderricin through water-accelerated [3,3]-sigmatropic rearrangement. **Bulletin of the Korean Chemical Society**, vol. 34, no. 9, p. 2815–2818, 2013. <https://doi.org/10.5012/bkcs.2013.34.9.2815>.

KIM, S. Y.; KIM, D. H.; MOON, S. M.; SONG, J. Y.; HUH, H. J.; LEE, N. Y.; SHIN, S. J.; KOH, W. J.; JHUN, B. W. Association between 16S rRNA gene mutations and susceptibility to amikacin in *Mycobacterium avium* Complex and *Mycobacterium abscessus* clinical isolates. **Scientific Reports**, vol. 11, no. 1, p. 1–8, 2021. DOI 10.1038/s41598-021-85721-5. Available at: <https://doi.org/10.1038/s41598-021-85721-5>.

KIMURA, Y.; BABA, K. Antitumor and antimetastatic activities of *Angelica keiskei* roots, part 1: Isolation of an active substance, xanthoangelol. **International Journal of Cancer**, vol. 106, no. 3, p. 429–437, 2003. <https://doi.org/10.1002/ijc.11256>.

KIMURA, Y.; TANIGUCHI, M.; BABA, K. Antitumor and antimetastatic activities of 4-hydroxyderricin isolated from *Angelica keiskei* roots. **Planta Medica**, vol. 70, no. 3, p. 211–219, 2004. <https://doi.org/10.1055/s-2004-815537>.

KIRSCHNING, A.; YUSUBOV, M. S.; YUSUBOVA, R. Y.; CHI, K. W.; PARK, J. Y. M-lodosylbenzoic acid - A convenient recyclable reagent for highly efficient aromatic iodinations. **Beilstein Journal of Organic Chemistry**, vol. 3, no. February, p. 3–8, 2007. <https://doi.org/10.1186/1860-5397-3-19>.

KOBAYASHI, A.; HAGIHARA, K.; KAJIYAMA, S. ichiro; KANZAKI, H.; KAWAZU, K. Antifungal Compounds Induced in the Dual Culture with *Phytolacca americana* Callus and *Botrytis fabae*. **Zeitschrift fur Naturforschung - Section C Journal of Biosciences**, vol. 50, no. 5–6, p. 398–402, 1995. <https://doi.org/10.1515/znc-1995-5-610>.

KODANI, S.; HAYASHI, K.; TOKUYAMA, S.; HASHIMOTO, M.; KIMURA, T.; DOMBO, M.; KAWAGISHI, H. Occurrence and identification of chalcones from the culinary-medicinal cauliflower mushroom *Sparassis crispa* (Wulf.) Fr. (Aphyllphoromycetideae). **International Journal of Medicinal Mushrooms**, vol. 10, no. 4, p. 331–336, 2008. <https://doi.org/10.1615/IntJMedMushr.v10.i4.50>.

KOZAWA, M.; MORITA, N.; BABA, KIMIYE AND HATA, K. NII-Electronic Library Service. **Chemical Pharmaceutical Bulletin**, vol. 98, no. 43, p. 2091, 1978. Available at: <http://www.mendeley.com/research/geology-volcanic-history-eruptive-style-yakedake-volcano-group-central-japan/>.

KUMAR, S. N.; SIJI, J. V.; NAMBISAN, B.; MOHANDAS, C. Activity and synergistic interactions of stilbenes and antibiotic combinations against bacteria in vitro. **World Journal of Microbiology and Biotechnology**, vol. 28, no. 11, p. 3143–3150, 2012. <https://doi.org/10.1007/s11274-012-1124-0>.

KWEON, M.; LEE, H.; PARK, C.; CHOI, Y. H.; RYU, J. H. A chalcone from ashitaba (*Angelica keiskei*) stimulates myoblast differentiation and inhibits dexamethasone-induced muscle atrophy. **Nutrients**, vol. 11, no. 10, p. 1–13, 2019. <https://doi.org/10.3390/nu11102419>.

LEANDRO, L. F.; CARDOSO, M. J. O.; SILVA, S. D. C.; SOUZA, M. G. M.; VENEZIANI, R. C. S.; AMBROSIO, S. R.; MARTINS, C. H. G. Antibacterial activity of *Pinus elliottii* and its major compound, dehydroabietic acid, against multidrug-resistant strains. **Journal of Medical Microbiology**, vol. 63, p. 1649–1653, 2014. <https://doi.org/10.1099/jmm.0.081711-0>.

LEE, M. R.; HUANG, Y. P.; KUO, Y. T.; LUO, C. H.; SHIH, Y. J.; SHU, C. C.; WANG, J. Y.; KO, J. C.; YU, C. J.; LIN, H. H. Diabetes Mellitus and Latent Tuberculosis Infection: A Systemic Review and Metaanalysis. **Clinical infectious diseases : an official publication of the Infectious Diseases Society of America**, vol. 64, no. 6, p. 719–727, 2017. <https://doi.org/10.1093/cid/ciw836>.

LEGER, A. J.; COVIC, L.; KULIOPULOS, A. Protease-activated receptors in cardiovascular diseases. **Circulation**, vol. 114, no. 10, p. 1070–1077, 2006. <https://doi.org/10.1161/CIRCULATIONAHA.105.574830>.

LEO, A.; HANSCH, C.; ELKINS, D. Partition coefficients and their uses. **Chemical Reviews**, vol. 71, no. 6, p. 525–616, 1971. <https://doi.org/10.1021/cr60274a001>.

LEWIS, R. E.; DIEKEMA, D. J.; MESSER, S. A.; PFALLER, M. A.; KLEPSE, M. E. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against *Candida* species. **Journal of Antimicrobial Chemotherapy**, vol. 49, no. 2, p. 345–351, 2002. <https://doi.org/10.1093/jac/49.2.345>.

LI, Y.; GOTO, T.; IKUTANI, R.; LIN, S.; TAKAHASHI, N.; TAKAHASHI, H.; JHENG, H. F.; YU, R.; TANIGUCHI, M.; BABA, K.; MURAKAMI, S.; KAWADA, T. Xanthoangelol and 4-hydroxyderrcin suppress obesity-induced inflammatory responses. **Obesity**, vol. 24, no. 11, p. 2351–2360, 2016. <https://doi.org/10.1002/oby.21611>.

LI, Y.; GOTO, T.; YAMAKUNI, K.; TAKAHASHI, H.; TAKAHASHI, N.; JHENG, H. F.; NOMURA, W.; TANIGUCHI, M.; BABA, K.; MURAKAMI, S.; KAWADA, T. 4-Hydroxyderricin, as a PPAR γ Agonist, Promotes Adipogenesis, Adiponectin Secretion, and Glucose Uptake in 3T3-L1 Cells. **Lipids**, vol. 51, no. 7, p. 787–795, 2016. <https://doi.org/10.1007/s11745-016-4154-9>.

LIANG, P. P.; HUANG, X. Z.; YI, J. L.; CHEN, Z. R.; MA, H.; YE, C. X.; CHEN, X. Y.; LAI, W.; CHEN, J. A trichophyton Rubrum infection model based on the reconstructed human epidermis - Episkin®. **Chinese Medical Journal**, vol. 129, no. 1, p. 54–58, 2016. <https://doi.org/10.4103/0366-6999.172573>.

LIPINSKI, C. A.; LOMBARDO, F.; DOMINY, B. W.; FEENEY, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. **Advanced Drug Delivery Reviews**, vol. 23, no. 6, p. 3–25, 1997. .

LIPINSKI, C. A.; LOMBARDO, F.; DOMINY, B. W.; FEENEY, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. **Advanced Drug Delivery Reviews**, vol. 46, no. SUPPL., p. 3–26, 2001. <https://doi.org/10.1016/j.addr.2012.09.019>.

LISTER, J. L.; HORSWILL, A. R. Staphylococcus aureus biofilms: Recent developments in biofilm dispersal. **Frontiers in Cellular and Infection Microbiology**, vol. 4, no. DEC, p. 1–9, 2014. <https://doi.org/10.3389/fcimb.2014.00178>.

LOWY, F. STAPHYLOCOCCUS AUREUS INFECTIONS. **New England Journal of Medicine**, vol. 339, p. 520–532, 1998. Available at: <http://www.nejm.org/doi/full/10.1056/NEJM199808203390806>.

LUNDE, C. S.; KUBO, I. Effect of polygodial on the mitochondrial ATPase of Saccharomyces cerevisiae. **Antimicrobial Agents and Chemotherapy**, vol. 44, no. 7, p. 1943–1953, 2000. <https://doi.org/10.1128/AAC.44.7.1943-1953.2000>.

LUO, L.; WANG, R.; WANG, X.; MA, Z.; LI, N. Compounds from Angelica keiskei with NQO1 induction, DPPH scavenging and α -glucosidase inhibitory activities. **Food Chemistry**, vol. 131, no. 3, p. 992–998, 2012. DOI 10.1016/j.foodchem.2011.09.099. Available at: <http://dx.doi.org/10.1016/j.foodchem.2011.09.099>.

LUO, T.; XU, P.; ZHANG, Y.; PORTER, J. L.; GHANEM, M.; LIU, Q.; JIANG, Y.; LI, J.; MIAO, Q.; HU, B.; HOWDEN, B. P.; FYFE, J. A. M.; GLOBAN, M.; HE, W.; HE, P.; WANG, Y.; LIU, H.; TAKIFF, H. E.; ZHAO, Y.; ... GAO, Q. Population genomics provides insights into the evolution and adaptation to humans of the waterborne pathogen Mycobacterium kansasii. **Nature Communications**, vol. 12, no. 1, p. 1–12, 2021. DOI 10.1038/s41467-021-22760-6. Available at: <http://dx.doi.org/10.1038/s41467-021-22760-6>.

MAHAPATRA, D. K.; BHARTI, S. K.; ASATI, V. Chalcone Derivatives: Anti-inflammatory Potential and Molecular Targets Perspectives. **Current Topics in Medicinal Chemistry**, vol. 17, no. 28, p. 3146–3169, 2017. <https://doi.org/10.2174/1568026617666170914160446>.

MAHAPATRA, D. K.; BHARTI, S. K.; ASATI, V. Chalcone scaffolds as anti-infective agents: Structural and molecular target perspectives. **European Journal of Medicinal Chemistry**, vol. 101, p. 496–524, 2015. DOI 10.1016/j.ejmech.2015.06.052. Available at: <http://dx.doi.org/10.1016/j.ejmech.2015.06.052>.

MALIK, N.; DHIMAN, P.; KHATKAR, A. In-silico Design and ADMET Studies of Natural Compounds as Inhibitors of Xanthine Oxidase (XO) Enzyme. **Current Drug Metabolism**, vol. 18, no. 6, p. 577–593, 2017. <https://doi.org/10.2174/1389200218666170316092531>.

MANNER, S.; VAHERMO, M.; SKOGMAN, M. E.; KROGERUS, S.; VUORELA, P. M.; YLIKAUHALUOMA, J.; FALLARERO, A.; MOREIRA, V. M. New derivatives of dehydroabietic acid target planktonic and biofilm bacteria in *S. taphylococcus aureus* and effectively disrupt bacterial membrane integrity. **European Journal of Medicinal Chemistry**, vol. 102, p. 68–79, 2015. <https://doi.org/10.1016/j.ejmech.2015.07.038>.

MARONPOT, R. R. Toxicological assessment of Ashitaba Chalcone. **Food and Chemical Toxicology**, vol. 77, no. 946, p. 111–119, 2015. DOI 10.1016/j.fct.2014.12.021. Available at: <http://dx.doi.org/10.1016/j.fct.2014.12.021>.

MARTINS, P. M. M.; LAU, I. F.; BACCI, M.; BELASQUE, J.; DO AMARAL, A. M.; TABOGA, S. R.; FERREIRA, H. Subcellular localization of proteins labeled with GFP in *Xanthomonas citri* ssp. *citri*: Targeting the division septum. **FEMS Microbiology Letters**, vol. 310, no. 1, p. 76–83, 2010. <https://doi.org/10.1111/j.1574-6968.2010.02047.x>.

MASAHARU MATSUURA, YOSHIYUKI KIMURA, KOJI NAKATA, KIMIYE BABA, H. O. Artery Relaxation by Chalcones Isolated from the Roots of *Angelica keiskei*. vol. 4, no. 2, p. 55–62, 2000. .

MASTIHUBOVÁ, M.; POLÁKOVÁ, M. A selective and mild glycosylation method of natural phenolic alcohols. **Beilstein Journal of Organic Chemistry**, vol. 12, no. Figure 1, p. 524–530, 2016. <https://doi.org/10.3762/bjoc.12.51>.

MCCARTHY, H.; RUDKIN, J. K.; BLACK, N. S.; GALLAGHER, L.; O'NEILL, E.; O'GARA, J. P. Methicillin resistance and the biofilm phenotype in *staphylococcus aureus*. **Frontiers in Cellular and Infection Microbiology**, vol. 5, no. January, p. 1–9, 2015. <https://doi.org/10.3389/fcimb.2015.00001>.

METHODS FOR DILUTION ANTIMICROBIAL SUSCEPTIBILITY TESTS FOR BACTERIA THAT GROW AEROBICALLY ; APPROVED STANDARD — NINTH EDITION. [S. l.: s. n.], 2012. vol. 32, .

MIRANDA, C. L.; APONSO, G. L. M.; STEVENS, J. F.; DEINZER, M. L.; BUHLER, D. R. Prenylated chalcones and flavanones as inducers of quinone reductase in mouse Hepa 1c1c7 cells. **Cancer Letters**, vol. 149, no. 1–2, p. 21–29, 2000. [https://doi.org/10.1016/S0304-3835\(99\)00328-6](https://doi.org/10.1016/S0304-3835(99)00328-6).

MIRANDA, Cristobal L.; STEVENS, J. F.; IVANOV, V.; MCCALL, M.; FREI, B.; DEINZER, M. L.; BUHLER, D. R. Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. **Journal of Agricultural and Food Chemistry**, vol. 48, no. 9, p. 3876–3884, 2000. <https://doi.org/10.1021/jf0002995>.

MIRZA-AGHAYAN, M.; BOUKHERROUB, R.; BOLOURTCHIAN, M.; RAHIMIFARD, M. Palladium catalyzed mild reduction of α,β -unsaturated compounds by triethylsilane. **Journal of Organometallic Chemistry**, vol. 692, no. 23, p. 5113–5116, 2007. <https://doi.org/10.1016/j.jorganchem.2007.08.017>.

MIYAURA, N.; SUZUKI, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. no. I, p. 2457–2483, 1995. <https://doi.org/10.1021/cr00039a007>.

MOGASALE, V. V.; SALDANHA, P.; PAI, V.; REKHA, P. D.; MOGASALE, V. A descriptive analysis of antimicrobial resistance patterns of WHO priority pathogens isolated in children from a tertiary care hospital in India. **Scientific Reports**, vol. 11, no. 1, p. 1–7, 2021. DOI 10.1038/s41598-021-84293-8. Available at: <https://doi.org/10.1038/s41598-021-84293-8>.

MORÃO, L. G.; POLAQUINI, C. R.; KOPACZ, M.; TORREZAN, G. S.; AYUSSO, G. M.; DILARRI, G.; CAVALCA, L. B.; ZIELIŃSKA, A.; SCHEFFERS, D. J.; REGASINI, L. O.; FERREIRA, H. A simplified curcumin targets the membrane of *Bacillus subtilis*. **MicrobiologyOpen**, vol. 8, no. 4, p. 1–12, 2019. <https://doi.org/10.1002/mbo3.683>.

NAKAMURA, T.; TOKUSHIMA, T.; KAWABATA, K.; YAMAMOTO, N.; MIYAMOTO, M.; ASHIDA, H. Absorption and metabolism of 4-hydroxyderricin and xanthoangelol after oral administration of *Angelica keiskei* (Ashitaba) extract in mice. **Archives of Biochemistry and Biophysics**, vol. 521, no. 1–2, p. 71–76, 2012. DOI 10.1016/j.abb.2012.03.013. Available at: <http://dx.doi.org/10.1016/j.abb.2012.03.013>.

NAVARRO, M. O. P.; DILARRI, G.; SIMIONATO, A. S.; GRZEGORCZYK, K.; DEALIS, M. L.; CANO, B. G.; BARAZETTI, A. R.; AFONSO, L.; CHRYSSAFIDIS, A. L.; FERREIRA, H.; ANDRADE, G. Determining the Targets of Fluopsin C Action on Gram-Negative and Gram-Positive Bacteria. **Frontiers in Microbiology**, vol. 11, no. June, p. 1–11, 2020. <https://doi.org/10.3389/fmicb.2020.01076>.

NEWMAN, D. J.; CRAGG, G. M. Natural Products as Sources of New Drugs from 1981 to 2014. **Journal of Natural Products**, vol. 79, no. 3, p. 629–661, 2016. <https://doi.org/10.1021/acs.jnatprod.5b01055>.

NISHIMURA, R.; TABATA, K.; ARAKAWA, M.; ITO, Y.; KIMURA, Y.; AKIHISA, T.; NAGAI, H.; SAKUMA, A.; KOHNO, H.; SUZUKI, T. Isobavachalcone, a chalcone constituent of *Angelica keiskei*, induces apoptosis in neuroblastoma. **Biological and Pharmaceutical Bulletin**, vol. 30, no. 10, p. 1878–1883, 2007. <https://doi.org/10.1248/bpb.30.1878>.

ODDS, F. C. Synergy, antagonism, and what the checkerboard puts between them. **Journal of Antimicrobial Chemotherapy**, vol. 52, no. 1, p. 1, 2003. <https://doi.org/10.1093/jac/dkg301>.

OECD. OECD117 guideline for testing of chemicals: Partitioning coefficient (n-octanol/water) HPLC method. , p. 1–11, 1989. .

OGAWA, H.; OHNO, M.; BABA, K. Hypotensive and lipid regulatory actions of 4-hydroxyderricin, a chalcone from *Angelica keiskei*, in stroke-prone spontaneously hypertensive rats. **Clinical and Experimental Pharmacology and Physiology**, vol. 32, no. 1–2, p. 19–23, 2005. <https://doi.org/10.1111/j.1440-1681.2005.04147.x>.

OH, H. A.; LEE, H.; PARK, S. yeon; LIM, Y.; KWON, O.; KIM, J. Y.; KIM, D.; JUNG, B. H. Analysis of plasma metabolic profiling and evaluation of the effect of the intake of *Angelica keiskei* using metabolomics and lipidomics. **Journal of Ethnopharmacology**, vol. 243, no. July, p. 112058, 2019. DOI 10.1016/j.jep.2019.112058. Available at: <https://doi.org/10.1016/j.jep.2019.112058>.

OH, J. M.; KANG, M. G.; HONG, A.; PARK, J. E.; KIM, S. H.; LEE, J. P.; BAEK, S. C.; PARK, D.; NAM, S. J.; CHO, M. L.; KIM, H. Potent and selective inhibition of human monoamine oxidase-B by 4-dimethylaminochalcone and selected chalcone derivatives. **International Journal of Biological Macromolecules**, vol. 137, p. 426–432, 2019. DOI 10.1016/j.ijbiomac.2019.06.167. Available at: <https://doi.org/10.1016/j.ijbiomac.2019.06.167>.

OHKURA, N.; OHNISHI, K.; TANIGUCHI, M.; NAKAYAMA, A.; USUBA, Y.; FUJITA, M.; FUJII, A.; ISHIBASHI, K.; BABA, K.; ATSUMI, G. Anti-platelet effects of chalcones from *Angelica keiskei* Koidzumi (*Ashitaba*) in vivo. **Pharmazie**, vol. 71, no. 11, p. 651–654, 2016. <https://doi.org/10.1691/ph.2016.6678>.

OHLSEN, K.; LORENZ, U. Novel targets for antibiotics in *Staphylococcus aureus*. **Future Microbiology**, vol. 2, no. 6, p. 655–666, 2007. <https://doi.org/10.2217/17460913.2.6.655>.

OHNOGI, H.; KUDO, Y.; TAHARA, K.; SUGIYAMA, K.; ENOKI, T.; HAYAMI, S.; SAGAWA, H.; TANIMURA, Y.; AOI, W.; NAITO, Y.; KATO, I.; YOSHIKAWA, T. Six new chalcones from *Angelica keiskei* inducing adiponectin production in 3T3-L1 adipocytes. **Bioscience, Biotechnology and Biochemistry**, vol. 76, no. 5, p. 961–966, 2012. <https://doi.org/10.1271/bbb.110976>.

OHTA, M.; FUJINAMI, A.; KOBAYASHI, N.; AMANO, A.; ISHIGAMI, A.; TOKUDA, H.; SUZUKI, N.; ITO, F.; MORI, T.; SAWADA, M.; IWASA, K.; KITAWAKI, J.; OHNISHI, K.; TSUJIKAWA, M.; OBAYASHI, H. Two chalcones, 4-hydroxyderricin and xanthoangelol, stimulate GLUT4-dependent glucose uptake through the LKB1/AMP-activated protein kinase signaling pathway in 3T3-L1 adipocytes. **Nutrition Research**, vol. 35, no. 7, p. 618–625, 2015. DOI 10.1016/j.nutres.2015.05.010. Available at: <http://dx.doi.org/10.1016/j.nutres.2015.05.010>.

OKUYAMA, T.; TAKATA, M.; TAKAYASU, J.; HASEGAWA, T.; TOKUDA, H.; NISHINO, A.; NISHINO, N.; IWASHIMA, A. Anti-tumor-promotion by principles obtained from *Angelica keiskei*. **Planta Medica**, vol. 57, no. 3, p. 242–246, 1991. <https://doi.org/10.1055/s-2006-960082>.

OSÓRIO, T. M.; MONACHE, F. D.; CHIARADIA, L. D.; MASCARELLO, A.; STUMPF, T. R.; ZANETTI, C. R.; SILVEIRA, D. B.; BARARDI, C. R. M.; SMÂNIA, E. D. F. A.; VIANCELLI,

A.; GARCIA, L. A. T.; YUNES, R. A.; NUNES, R. J.; SMÂNIA, A. Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant *Staphylococcus aureus*. **Bioorganic and Medicinal Chemistry Letters**, vol. 22, no. 1, p. 225–230, 2012. <https://doi.org/10.1016/j.bmcl.2011.11.059>.

PALOMINO, J. C.; MARTIN, A.; CAMACHO, M.; GUERRA, H.; SWINGS, J.; PORTAELS, F. Resazurin microtiter assay plate: Simple and inexpensive method for detection of drug resistance in *Mycobacterium tuberculosis*. **Antimicrobial Agents and Chemotherapy**, vol. 46, no. 8, p. 2720–2722, 2002. <https://doi.org/10.1128/AAC.46.8.2720-2722.2002>.

PARK, J. Y.; JEONG, H. J.; KIM, Y. M.; PARK, S. J.; RHO, M. C.; PARK, K. H.; RYU, Y. B.; LEE, W. S. Characteristic of alkylated chalcones from *Angelica keiskei* on influenza virus neuraminidase inhibition. **Bioorganic and Medicinal Chemistry Letters**, vol. 21, no. 18, p. 5602–5604, 2011. DOI 10.1016/j.bmcl.2011.06.130. Available at: <http://dx.doi.org/10.1016/j.bmcl.2011.06.130>.

PARK, J. Y.; KO, J. A.; KIM, D. W.; KIM, Y. M.; KWON, H. J.; JEONG, H. J.; KIM, C. Y.; PARK, K. H.; LEE, W. S.; RYU, Y. B. Chalcones isolated from *Angelica keiskei* inhibit cysteine proteases of SARS-CoV. **Journal of Enzyme Inhibition and Medicinal Chemistry**, vol. 31, no. 1, p. 23–30, 2016. <https://doi.org/10.3109/14756366.2014.1003215>.

PARK, S.; KIM, J. G.; SHIN, Y. K.; KIM, K. Y. Antimicrobial activity of 4-hydroxyderricin, sophoraflavanone G, acetylshikonin, and kurarinone against the bee pathogenic bacteria *Paenibacillus larvae* and *Melissococcus plutonius*. **Journal of Apicultural Research**, vol. 60, no. 1, p. 118–122, 2021. DOI 10.1080/00218839.2020.1746018. Available at: <https://doi.org/10.1080/00218839.2020.1746018>.

PEREIRA, J. A.; POLAQUINI, C. R.; DOS SANTOS, V.; CAIAFFA, K. S.; RABELO, R. L.; DOS SANTOS THEODORO, R.; THEODORO, L. H.; REGASINI, L. O.; DUQUE, C. Antibiofilm and cytotoxic effect of 3,3'-dihydroxycurcumin (DHC) as photosensitizer agent in antimicrobial photodynamic therapy for endodontic purposes. **Photodiagnosis and Photodynamic Therapy**, vol. 36, no. September, p. 102534, 2021. DOI 10.1016/j.pdpdt.2021.102534. Available at: <https://doi.org/10.1016/j.pdpdt.2021.102534>.

PODUNAVAC-KUZMANOVIĆ, S. O.; CVETKOVIĆ, D. D.; BARNA, D. J. The effect of lipophilicity on the antibacterial activity of some 1-benzylbenzimidazole derivatives. **Journal of the Serbian Chemical Society**, vol. 73, no. 10, p. 967–978, 2008. <https://doi.org/10.2298/JSC0810967P>.

POOLE, A.; GIBBINS, J. M.; TURNER, M.; VAN VUGT, M. J.; VAN DE WINKEL, J. G. J.; SAITO, T.; TYBULEWICZ, V. L. J.; WATSON, S. P. The Fc receptor γ -chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. **EMBO Journal**, vol. 16, no. 9, p. 2333–2341, 1997. <https://doi.org/10.1093/emboj/16.9.2333>.

PRESTINACI, F.; PEZZOTTI, P.; PANTOSTI, A. Antimicrobial resistance: A global multifaceted phenomenon. **Pathogens and Global Health**, vol. 109, no. 7, p. 309–318, 2015. DOI 10.1179/2047773215Y.0000000030. Available at:

<http://dx.doi.org/10.1179/2047773215Y.00000000030>.

RAIMONDI, M. V.; MAGGIO, B.; RAFFA, D.; PLESCIA, F.; CASCIOFERRO, S.; CANCEMI, G.; SCHILLACI, D.; CUSIMANO, M. G.; VITALE, M.; DAIDONE, G. Synthesis and anti-staphylococcal activity of new 4-diazopyrazole derivatives. **European Journal of Medicinal Chemistry**, vol. 58, p. 64–71, 2012. DOI 10.1016/j.ejmech.2012.09.041. Available at: <http://dx.doi.org/10.1016/j.ejmech.2012.09.041>.

RAN, Y.; HE, Y.; YANG, G.; JOHNSON, J. L. H.; YALKOWSKY, S. H. Estimation of aqueous solubility of organic compounds by using the general solubility equation. **Chemosphere**, vol. 48, no. 5, p. 487–509, 2002. [https://doi.org/10.1016/S0045-6535\(02\)00118-2](https://doi.org/10.1016/S0045-6535(02)00118-2).

RAN, Y.; JAIN, N.; YALKOWSKY, S. H. Prediction of Aqueous Solubility of Organic Compounds by the General Solubility Equation (GSE). **J. Chem. Inf. Comput. Sci**, vol. 41, p. 1208–1217, 2001. <https://doi.org/10.1002/qsar.200330822>.

REISS, E.; HEARN, V. M.; POULAIN, D.; SHEPHERD, M. G. Structure and function of the fungal cell wall. **Medical Mycology**, vol. 30, no. S1, p. 143–156, 1992. <https://doi.org/10.1080/02681219280000841>.

RICE, L. B. Progress and Challenges in Implementing the Research on ESKAPE Pathogens. **Infection Control & Hospital Epidemiology**, vol. 31, no. S1, p. S7–S10, 2010. <https://doi.org/10.1086/655995>.

ROCHA, J. E.; DE FREITAS, T. S.; DA CUNHA XAVIER, J.; PEREIRA, R. L. S.; JUNIOR, F. N. P.; NOGUEIRA, C. E. S.; MARINHO, M. M.; BANDEIRA, P. N.; DE OLIVEIRA, M. R.; MARINHO, E. S.; TEIXEIRA MARINHO, A. M. R.; DOS SANTOS MARINHO, H. S.; COUTINHO, H. D. M. Antibacterial and antibiotic modifying activity, ADMET study and molecular docking of synthetic chalcone (E)-1-(2-hydroxyphenyl)-3-(2,4-dimethoxy-3-methylphenyl)prop-2-en-1-one in strains of *Staphylococcus aureus* carrying NorA and MepA efflux pumps. **Biomedicine and Pharmacotherapy**, vol. 140, no. April, 2021. <https://doi.org/10.1016/j.biopha.2021.111768>.

ROZMER, Z.; PERJÉSI, P. Naturally occurring chalcones and their biological activities. **Phytochemistry Reviews**, vol. 15, no. 1, p. 87–120, 2016. <https://doi.org/10.1007/s11101-014-9387-8>.

SANGHVI, T.; JAIN, N.; YANG, G.; YALKOWSKY, S. H. Estimation of aqueous solubility by the General Solubility Equation (GSE) the easy way. **QSAR and Combinatorial Science**, vol. 22, no. 2, p. 258–262, 2003. <https://doi.org/10.1002/qsar.200390020>.

SARKER, S. D.; NAHAR, L.; KUMARASAMY, Y. Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicals. **Methods**, vol. 42, no. 4, p. 321–324, 2007. DOI 10.1016/j.ymeth.2007.01.006. Available at: <http://dx.doi.org/10.1016/j.ymeth.2007.01.006>.

SAYED, A. M.; KHATTAB, A. R.; ABOULMAGD, A. M.; HASSAN, H. M.; RATEB, M. E.;

ZAID, H.; ABDELMOHSEN, U. R. Nature as a treasure trove of potential anti-SARS-CoV drug leads: a structural/mechanistic rationale. **RSC Advances**, vol. 10, no. 34, p. 19790–19802, 2020. <https://doi.org/10.1039/d0ra04199h>.

SEAN E. ROSSITER, MADISON H. FLETCHER, and W. M. W. Natural Products as Platforms To Overcome Antibiotic Resistance. **HHS Public Access**, vol. 176, no. 3, p. 139–148, 2017. <https://doi.org/10.1021/acs.chemrev.7b00283>.Natural.

SEO, M. D.; KANG, T. J.; LEE, C. H.; LEE, A. Y.; NOH, M. HaCa T keratinocytes and primary epidermal keratinocytes have different transcriptional profiles of cornified envelope-associated genes to T helper cell cytokines. **Biomolecules and Therapeutics**, vol. 20, no. 2, p. 171–176, 2012. <https://doi.org/10.4062/biomolther.2012.20.2.171>.

SHIMOMURA, K.; INUI, S.; SUGIYAMA, Y.; KUROSAWA, M.; NAKAMURA, J.; CHOI, S. J.; AHN, M. R.; KUMAZAWA, S. Identification of the plant origin of propolis from jeju Island, Korea, by observation of honeybee behavior and phytochemical analysis. **Bioscience, Biotechnology and Biochemistry**, vol. 76, no. 11, p. 2135–2138, 2012. <https://doi.org/10.1271/bbb.120580>.

SHIMOMURA, K.; SUGIYAMA, Y.; NAKAMURA, J.; AHN, M. R.; KUMAZAWA, S. Component analysis of propolis collected on Jeju Island, Korea. **Phytochemistry**, vol. 93, p. 222–229, 2013. DOI 10.1016/j.phytochem.2012.02.018. Available at: <http://dx.doi.org/10.1016/j.phytochem.2012.02.018>.

SHIN, J. E.; CHOI, E. J.; JIN, Q.; JIN, H. G.; WOO, E. R. Chalcones isolated from angelica keiskei and their inhibition of IL-6 production in TNF- α -stimulated MG-63 cell. **Archives of Pharmacal Research**, vol. 34, no. 3, p. 437–442, 2011. <https://doi.org/10.1007/s12272-011-0311-0>.

SILVA-ROCHA, W. P.; DE AZEVEDO, M. F.; CHAVES, G. M. Épidémiologie et distribution des espèces fongiques des mycoses superficielles dans le Nord-est du Brésil. **Journal de Mycologie Médicale**, vol. 27, no. 1, p. 57–64, 2017. DOI 10.1016/j.mycmed.2016.08.009. Available at: <http://dx.doi.org/10.1016/j.mycmed.2016.08.009>.

SILVA, I. C.; REGASINI, L. O.; PETRÃO, M. S.; SILVA, D. H. S.; BOLZANI, V. S.; BELASQUE, J.; SACRAMENTO, L. V. S.; FERREIRA, H. Antibacterial activity of alkyl gallates against *Xanthomonas citri* subsp. *citri*. **Journal of Bacteriology**, vol. 195, no. 1, p. 85–94, 2013. <https://doi.org/10.1128/JB.01442-12>.

SIOPI, M.; EFSTATHIOU, I.; THEODOROPOULOS, K.; POURNARAS, S.; MELETIADIS, J. Molecular epidemiology and antifungal susceptibility of trichophyton isolates in greece: emergence of terbinafine-resistant trichophyton mentagrophytes type viii locally and globally. **Journal of Fungi**, vol. 7, no. 6, 2021. <https://doi.org/10.3390/jof7060419>.

SON, D. J.; PARK, Y. O.; YU, C.; LEE, S. E.; PARK, Y. H. Bioassay-guided isolation and identification of anti-platelet-active compounds from the root of Ashitaba (*Angelica keiskei* Koidz.). **Natural Product Research**, vol. 28, no. 24, p. 2312–2316, 2014. <https://doi.org/10.1080/14786419.2014.931389>.

SONG, Z.; BORGWARDT, L.; HØIBY, N.; WU, H.; SØRENSEN, T. S.; BORGWARDT, A. Prosthesis infections after orthopedic joint replacement: the possible role of bacterial biofilms. **Orthopedic Reviews**, vol. 5, no. 2, p. 14, 2013. <https://doi.org/10.4081/or.2013.e14>.

SONMEZ, F.; SEVMEZLER, S.; ATAHAN, A.; CEYLAN, M.; DEMIR, D.; GENCER, N.; ARSLAN, O.; KUCUKISLAMOGLU, M. Evaluation of new chalcone derivatives as polyphenol oxidase inhibitors. **Bioorganic and Medicinal Chemistry Letters**, vol. 21, no. 24, p. 7479–7482, 2011. DOI 10.1016/j.bmcl.2011.09.130. Available at: <http://dx.doi.org/10.1016/j.bmcl.2011.09.130>.

SOUZA, N. A. B.; DE OLIVEIRA LIMA, E.; GUEDES, D. N.; DE OLIVEIRA PEREIRA, F.; DE SOUZA, E. L.; DE SOUSA, F. B. Efficacy of Origanum essential oils for inhibition of potentially pathogenic fungi. **Brazilian Journal of Pharmaceutical Sciences**, vol. 46, no. 3, p. 499–508, 2010. <https://doi.org/10.1590/s1984-82502010000300013>.

SPÓSITO, L.; ODA, F. B.; VIEIRA, J. H.; CARVALHO, F. A.; DOS SANTOS RAMOS, M. A.; DE CASTRO, R. C.; CREVELIN, E. J.; CROTTI, A. E. M.; SANTOS, A. G.; DA SILVA, P. B.; CHORILLI, M.; BAUAB, T. M. In vitro and in vivo anti-Helicobacter pylori activity of Casearia sylvestris leaf derivatives. **Journal of Ethnopharmacology**, vol. 233, no. December 2018, p. 1–12, 2019. DOI 10.1016/j.jep.2018.12.032. Available at: <https://doi.org/10.1016/j.jep.2018.12.032>.

STEWART, P. S. Antimicrobial Tolerance in Biofilms EXAMPLES OF REDUCED BIOFILM SUSCEPTIBILITY. vol. 3, no. 3, p. 1–30, 2015. <https://doi.org/10.1128/microbiolspec.MB-0010-2014.Antimicrobial>.

SUGAMOTO, K.; KUROGI, C.; MATSUSHITA, Y. ichi; MATSUI, T. Synthesis of 4-hydroxyderricin and related derivatives. **Tetrahedron Letters**, vol. 49, no. 47, p. 6639–6641, 2008. DOI 10.1016/j.tetlet.2008.09.015. Available at: <http://dx.doi.org/10.1016/j.tetlet.2008.09.015>.

SUGAMOTO, K.; MATSUSITA, Y. I.; MATSUI, K.; KUROGI, C.; MATSUI, T. Synthesis and antibacterial activity of chalcones bearing prenyl or geranyl groups from Angelica keiskei. **Tetrahedron**, vol. 67, no. 29, p. 5346–5359, 2011. DOI 10.1016/j.tet.2011.04.104. Available at: <http://dx.doi.org/10.1016/j.tet.2011.04.104>.

SUMIYOSHI, M.; TANIGUCHI, M.; BABA, K.; KIMURA, Y. Antitumor and antimetastatic actions of xanthoangelol and 4-hydroxyderricin isolated from Angelica keiskei roots through the inhibited activation and differentiation of M2 macrophages. **Phytomedicine**, vol. 22, no. 7–8, p. 759–767, 2015. DOI 10.1016/j.phymed.2015.05.005. Available at: <http://dx.doi.org/10.1016/j.phymed.2015.05.005>.

TAKAOKA, S.; HIBASAMI, H.; OGASAWARA, K.; IMAI, N. Chalcones from angelica keiskei induce apoptosis in stomach cancer cells. **Journal of Herbs, Spices and Medicinal Plants**, vol. 14, no. 3–4, p. 166–174, 2008. <https://doi.org/10.1080/10496470802598727>.

TASSE, J.; CROISIER, D.; BADEL-BERCHOUX, S.; CHAVANET, P.; BERNARDI, T.;

PROVOT, C.; LAURENT, F. Preliminary results of a new antibiotic susceptibility test against biofilm installation in device-associated infections: The Antibiofilmogram ®. **Pathogens and Disease**, vol. 74, no. 6, p. 1–7, 2016. <https://doi.org/10.1093/femspd/ftw057>.

TAUBENBERGER, J. K.; MORENS, D. M. Influenza: The once and future pandemic. **Public Health Reports**, vol. 125, no. SUPPL. 3, p. 15–26, 2010. <https://doi.org/10.1177/00333549101250s305>.

UR RASHID, H.; XU, Y.; AHMAD, N.; MUHAMMAD, Y.; WANG, L. Promising anti-inflammatory effects of chalcones via inhibition of cyclooxygenase, prostaglandin E 2 , inducible NO synthase and nuclear factor kb activities. **Bioorganic Chemistry**, vol. 87, no. December 2018, p. 335–365, 2019. DOI 10.1016/j.bioorg.2019.03.033. Available at: <https://doi.org/10.1016/j.bioorg.2019.03.033>.

VENTURINI, J.; ROSSI-FERREIRA, R.; ARRUDA, M. S. P. Production OF Trichophyton mentagrophytes antigens and their characterization in mice. **Journal of Venomous Animals and Toxins Including Tropical Diseases**, vol. 14, no. 3, p. 409–422, 2008. <https://doi.org/10.1590/S1678-91992008000300003>.

VIEIRA, R. G. L.; MORAES, T. da S.; SILVA, L. de O.; BIANCHI, T. C.; VENEZIANI, R. C. S.; AMBRÓSIO, S. R.; BASTOS, J. K.; PIRES, R. H.; MARTINS, C. H. G. In vitro studies of the antibacterial activity of Copaifera spp. oleoresins, sodium hypochlorite, and peracetic acid against clinical and environmental isolates recovered from a hemodialysis unit. **Antimicrobial Resistance and Infection Control**, vol. 7, no. 1, p. 1–13, 2018. <https://doi.org/10.1186/s13756-018-0307-3>.

WANG, H. M.; ZHANG, L.; LIU, J.; YANG, Z. L.; ZHAO, H. Y.; YANG, Y.; SHEN, D.; LU, K.; FAN, Z. C.; YAO, Q. W.; ZHANG, Y. M.; TENG, Y. O.; PENG, Y. Synthesis and anti-cancer activity evaluation of novel prenylated and geranylated chalcone natural products and their analogs. **European Journal of Medicinal Chemistry**, vol. 92, p. 439–448, 2015. DOI 10.1016/j.ejmech.2015.01.007. Available at: <http://dx.doi.org/10.1016/j.ejmech.2015.01.007>.

WANG, M.; LIN, L.; LU, J. J.; CHEN, X. Pharmacological review of isobavachalcone, a naturally occurring chalcone. **Pharmacological Research**, vol. 165, no. September 2020, p. 105483, 2021. DOI 10.1016/j.phrs.2021.105483. Available at: <https://doi.org/10.1016/j.phrs.2021.105483>.

WANG, S.; YAN, J.; WANG, J.; CHEN, J.; ZHANG, T.; ZHAO, Y.; XUE, M. Synthesis of some 5-phenylisoxale-3-carboxylic acid derivatives as potent xanthine oxidase inhibitors. , p. 8, DOI: 10.1016/j.ejmech.2010.02.013, 2010. .

WEI, G. X.; CAMPAGNA, A. N.; BOBEK, L. A. Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm. **Journal of Antimicrobial Chemotherapy**, vol. 57, no. 6, p. 1100–1109, 2006. <https://doi.org/10.1093/jac/dkl120>.

WHITE, R. L.; BURGESS, D. S.; MANDURU, M.; BOSSO, J. A. Comparison of three different in vitro methods of detecting synergy: Time-kill, checkerboard, and E test. **Antimicrobial Agents and Chemotherapy**, vol. 40, no. 8, p. 1914–1918, 1996. <https://doi.org/10.1128/aac.40.8.1914>.

WHO. **Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics**. [S. l.: s. n.], 2017.

WHO. **Global Tuberculosis Report 2020**. [S. l.: s. n.], 2020.

WHO. Global Daly methods, Japan, 2011, WHO. **World Health Organization**, vol. 4, no. November, 2014. Available at: http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html.

WU, H.; MOSER, C.; WANG, H. Z.; HØIBY, N.; SONG, Z. J. Strategies for combating bacterial biofilm infections. **International Journal of Oral Science**, vol. 7, no. July 2014, p. 1–7, 2015. <https://doi.org/10.1038/ijos.2014.65>.

YAN, A.; GASTEIGER, J. Prediction of Aqueous Solubility of Organic Compounds by Topological Descriptors. **QSAR and Combinatorial Science**, vol. 22, no. 8, p. 821–829, 2003. <https://doi.org/10.1002/qsar.200330822>.

YASUDA, M.; KAWABATA, K.; MIYASHITA, M.; OKUMURA, M.; YAMAMOTO, N.; TAKAHASHI, M.; ASHIDA, H.; OHIGASHI, H. Inhibitory effects of 4-hydroxyderricin and xanthoangelol on lipopolysaccharide-induced inflammatory responses in RAW264 macrophages. **Journal of Agricultural and Food Chemistry**, vol. 62, no. 2, p. 462–467, 2013. <https://doi.org/10.1021/jf404175t>.

YASUDA, M.; KAWABATA, K.; MIYASHITA, M.; OKUMURA, M.; YAMAMOTO, N.; TAKAHASHI, M.; ASHIDA, H.; OHIGASHI, H. Inhibitory effects of 4-hydroxyderricin and xanthoangelol on lipopolysaccharide-induced inflammatory responses in RAW264 macrophages. **Journal of Agricultural and Food Chemistry**, vol. 62, no. 2, p. 462–467, 2014. <https://doi.org/10.1021/jf404175t>.

YOSHIOKA, Y.; SAMUKAWA, Y.; YAMASHITA, Y.; ASHIDA, H. 4-Hydroxyderricin and xanthoangelol isolated from: *Angelica keiskei* prevent dexamethasone-induced muscle loss. **Food and Function**, vol. 11, no. 6, p. 5498–5512, 2020. <https://doi.org/10.1039/d0fo00720j>.

ZHANG, T.; SAWADA, K.; YAMAMOTO, N.; ASHIDA, H. 4-Hydroxyderricin and xanthoangelol from *Ashitaba* (*Angelica keiskei*) suppress differentiation of preadipocytes to adipocytes via AMPK and MAPK pathways. **Molecular Nutrition and Food Research**, vol. 57, no. 10, p. 1729–1740, 2013. <https://doi.org/10.1002/mnfr.201300020>.

ZHANG, T.; WANG, Q.; FREDIMOSSES, M.; GAO, G.; WANG, K.; CHEN, H.; WANG, T.; OI, N.; ZYKOVA, T. A.; REDDY, K.; YAO, K.; MA, W.; CHANG, X.; LEE, M. H.; RATHORE, M. G.; BODE, A. M.; ASHIDA, H.; LIPPMAN, S. M.; DONG, Z. The *Ashitaba* (*Angelica keiskei*) Chalcones 4-hydroxyderricin and xanthoangelol suppress melanomagenesis by targeting BRAF and PI3K. **Cancer Prevention Research**, vol. 11, no. 10, p. 607–619, 2018. <https://doi.org/10.1158/1940-6207.CAPR-18-0092>.

ZHANG, T.; YAMAMOTO, N.; ASHIDA, H. Chalcones suppress fatty acid-induced lipid accumulation through a LKB1/AMPK signaling pathway in HepG2 cells. **Food and Function**, vol.

5, no. 6, p. 1134–1141, 2014. <https://doi.org/10.1039/c3fo60694e>.

ZHANG, T.; YAMASHITA, Y.; YASUDA, M.; YAMAMOTO, N.; ASHIDA, H. Ashitaba (*Angelica keiskei*) extract prevents adiposity in high-fat diet-fed C57BL/6 mice. **Food and Function**, vol. 6, no. 1, p. 135–145, 2015. <https://doi.org/10.1039/c4fo00525b>.

ZHANG, W.; LIU, W.; JIANG, X.; JIANG, F.; ZHUANG, H.; FU, L. Design, synthesis and antimicrobial activity of chiral 2-(substituted- hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives. **European Journal of Medicinal Chemistry**, vol. 46, no. 9, p. 3639–3650, 2011. DOI 10.1016/j.ejmech.2011.05.028. Available at: <http://dx.doi.org/10.1016/j.ejmech.2011.05.028>.

ZHUANG, C.; ZHANG, W.; SHENG, C.; ZHANG, W.; XING, C.; MIAO, Z. Chalcone: A Privileged Structure in Medicinal Chemistry. **Chemical Reviews**, vol. 117, no. 12, p. 7762–7810, 2017. <https://doi.org/10.1021/acs.chemrev.7b00020>.